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Gram-negative bacteria are able to cause many infections including blood stream 
infections (BSI).These bacteria may become resistant to antibiotics, often by 
acquiring genes in the presence of antibiotic selection pressure. Multi drug resistant 
Gram-negative bacteria have become an increasing problem worldwide. A study of 
antibiotic resistance in Gram-negative bacteria isolated from blood cultures from 
patients in the New Royal Infirmary of Edinburgh (NRIE) was performed. In addition, 
a study was performed on isolates from patients in an intensive care unit in Egypt. All 
isolates were investigated for susceptibility to an extensive range of antibiotics. 
 
Gram-negative bacteria from Edinburgh found to be resistant to either cefotaxime or 
ceftazidime were investigated further. Among the cefotaxime/ceftazidime resistant 
isolates, Polymerase Chain Reaction (PCR) analysis revealed the presence of CTX-M-
β-lactamases. Seven E.coli isolates were found to have CTX-M-15 β-lactamases while 
the CTX-M-14 β-lactamase was detected in six Enterobacter cloacae. The insertion 
sequence ISEcp1 was detected upstream of the blaCTX-M-15 gene in some isolates while 
IS26 was found truncating the ISEcp1 in other isolates. Conjugation experiments 
found the blaCTX-M-15 gene was transferable to E. coli J62-2. All the isolates had 
detectable plasmids, a plasmid ~260kb carried the blaCTX-M-15 gene. Analysis of the 
CTX-M-containing isolates by PFGE shows that those carrying the CTX-M-14 
β-lactamase were identical indicating cross infection within the hospital. The CTX-M-
15 β-lactamase-containing isolates showed four isolates had ≥85% similarity but the 
others were diverse. Class 1 integrons were found in eight of the CTX-M β-lactamase-
containing isolates with the associated gene cassette and sul1 gene. 
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The isolates from Egypt were found to be resistant to carbapenem, which is the final 
mainstream antibiotic option in the treatment of multidrug resistant Gram-negative 
bacteria. Further analysis revealed all carried the CTX-M-14 β-lactamase and two 
additionally carried the VIM-4 metallo β-lactamase, which accounted for the 
resistance to the carbapenems. Furthermore, the insertion sequence ISEcp1 was found 
upstream of the blaCTX-M-14 gene in two of the isolates. The blaVIM-4 gene was found to 
be part of the gene cassette in the class 1 integron associate with complex ISCR1. 
Two of the Egyptian isolates had a detectable plasmid, ~300kb in size, which carried 
both blaCTX-M-14  and blaVIM-4 genes. 
 
All the blood culture isolates were examined to ascertain the persistence of 
sulphonamide resistance despite the long-term prescribing reduction on this 
antibacterial. PCR was performed to detect sul1, sul2 and sul3 genes in all the 
isolates. Of the sulphonamide resistant isolates 25 carried the sul1, 27 carried the sul2 
and none carried the sul3 genes. Eight isolates had both the sul1 and sul2 genes. Most 
of the isolates carried sul1 had Int1 as part of the same class 1 integron. Interestingly 
three isolates were PCR negative for sul1 but positive for sul2 and int1. Int2 and 3 
were found in 3 and 2 isolates respectively. The class 1 integron contained different 
insert gene cassettes; dfrA (dfrA17, dfrA16, dfrA15), aadA (aadA5, aadA2, aadA1) 
and blaOXA-1 families in addition to the resident sul gene.  
 
In conclusion this thesis shows the diversity of  the genetic environment and carriers 
of the CTX-M β-lactamases within the same hospital. Sulphonamide resistance in 
Gram-negatives persists despite the prescribing reduction of this antibacterial in a 
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1.1 Antibiotics definition 
Strictly speaking antibiotics are natural microbial products, however, the definition is 
usually now extended also to include synthetic chemotherapeutic agents. These 
compounds kill or inhibit the growth and survival of microorganisms without causing 
any serious toxicity to the host. The term Antibiotics was coined by Selman Waksman 
an Ukrainian- American Biochemist and Microbiologist in 1942 (Waksman 1947).  
 
1.2 History and Development of Antibiotics 
 
The term ‘Magic Bullet’ was first used by Paul Ehrlich to describe a compound which 
has a ‘magical’ effect on bacterial infections by targeting a specific pathogen. The 
first magic bullet-Salvarsan was discovered by Erhlich and Hata in 1907 and caused a 
great excitement because of its ability to cure syphilis and other spirochaetes 
infections (Ehrlich and Bertheim 1912). However, Salvarsan had severe toxicity 
problems associated with its use and was unfortunately only effective against a single 
group of pathogens, namely Treponema spp. causing syphilis. Continuing in the same 
line of research as Ehrlich in the development of synthetic compounds, Gerhard 
Domagk discovered an antimicrobial agent that cured infections when given to 
animals. He found that the dye Prontosil cured a disease caused by Streptococcus 
pyogenea in mice (Domagk 1935).  
 
The discovery of natural antibiotics transformed medicine and began by accident in 
the morning of September 3rd 1928. Alexander Fleming was looking at some old 
plates and notices that colonies of Staphylococcus aureus had been lysed by the 
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product of a mould Penicillium chrysogenum in the adjacent area (Fleming 1929). 
Despite its early discovery, Penicillin was not available for commercial use until 1944 
because of the difficulty in purification and production. In 1943, Selman Waksman 
and his group isolated another antimicrobial agent from the soil bacterium 
Streptomyces griseus (Schatz et al. 1944). The antibiotic, streptomycin, proved 
effective against several common infections, most notably those caused by Gram-
negative bacteria, against which penicillin was ineffective, and especially the 
untouchable bacterium Mycobacterium tuberculosis, the microbe causing tuberculosis 
(Schatz and Waksman 1944). The use of streptomycin resulted in notable side effects 
(Kidney damage and deafness) that were absent with the use of penicillin. A second 
problem is bacteria developing resistance to the killing effect of streptomycin during 
therapy. 
 
In the following years antibiotics became available to all ensuring that their use rose 
exponentially. In these early years several new classes of both man made and 
naturally occurring antibiotics were discovered including cephalosporins (1945), 
erythromycin (1952), methicillin (1960), ampicillin (1961), gentamicin (1963). 
Cephalosporins were introduced in 1964 with multiple second and third generation 
compounds becoming available by mid-1980s (Shlaes et al. 2004). 
 
1.3 Antibiotics classes 
All antibiotics are grouped into classes by their pharmacological properties. 
Antibiotics have different chemical compound and provide different action. 
Antibiotics can also be classified as either bacteriostatic or bactericidal as shown in 
Table 1.  
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Table 1 Major classes of antibiotics 
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Polypepetides  Bactericidal Polymixin-B, Colistin, Bacitracin 
Lipopeptides  Bactericidal Daptomicin 
Glycopeptides  Bactericidal Teichplanin,Vancomycin,Telavancin 
Fosfomycin  Bactericidal Fosfomycin 
Aminoglycoside  Bactericidal Gentamicin,Amikacin,Neomycin 
Lincosamides  Bacteriostatic Lincomysin,Clindamycin 
Macrolides  Bacteriostatic Erythromicin,Spectinomycin, 
Quinolones  Bactericidal Ciprofloxacin, Nalidixic acid 
Sulphonamides  Bacteriostatic Sulphonamidochrysoidine,Sulphametizole 
Tetracyclines  Bacteriostatic Tetracycline, Doxycycline 
Oxazolidinoes  Bacteriostatic Linezolides 
Diaminopyrimidine  Bacteriostatic Trimethoprim, Iclaprime 
Nitroimidazole  Bactericidal Metronidazole 
Rifamycins  Bactericidal Rifampicin,Rifabutin, 
 
The table show the list of major antibiotic classes showing division between 
bacteristatic and bactericidal antibiotics with some example of each class.
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Bacteriostatic agents prevent bacteria from reproducing, while not necessarily 
harming them otherwise. Bacteriostatic antibiotics limit the growth of bacteria usually 
by interfering with bacterial protein production. Bactericidal antibiotics kill the 
bacteria, often by interfering with DNA synthesis. However, there is not always a 
precise distinction between them and high concentrations of some bacteriostatic 
agents can also become bactericidal, whereas low concentrations of some bactericidal 
agents are bacteriostatic. 
 
 
1.4 Antibiotics mechanism of action 
 
Different antibiotics have different modes of action due to the nature of their structure 
and the level of affinity to the target site within the bacterial cells. The antimicrobial 
effect of these compounds can be shown through their mechanisms of action.  
 
Inhibition of DNA synthesis: The most significant group of compounds acting 
against DNA synthesis are the fluoroquinolones. Fluoroquinolones act by inhibiting 
the DNA gyrases or topoisomerase IV required for supercoiling of DNA. Although 
some degree of overlap may exist, DNA gyrase tends to be the primary target for 
fluoroquinolones in Gram-negative organisms whereas topoisomerase IV is typically 
the primary target in Gram-positive bacteria (Hooper 1999). These two enzymes DNA 
gyrase and topoisomerases are trapped by fluoroquinolones on DNA  as drug 
/enzyme/DNA complex which blocks  progression of  replication fork there by  
inhibiting DNA  synthesis (Drlica 1999). DNA gyrase is composed of two GyrA and 
two GyrB monomeric subunits, which are encoded by the gyrA and gyrB genes, 
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respectively while the Topoisomerase IV is composed of four homologous 
monomeric subunits, two ParC subunits and two ParE subunits encoded by the parC 
and parE genes, respectively (Hooper 1999). 
 
Metronidazole although not a classic inhibitor of DNA synthesis also has an effect on 
the DNA by producing metabolic cytotoxic by-products that disrupt DNA. 
Metronidazole inhibits anaerobic bacteria and protozoans. The nitro group of the drug 
undergoes reductive activation and is reduced by low redox potential electron 
transport proteins. The resulting active compound damages the cell through 
interaction with DNA (Neu and Gootz 1996). 
 
Inhibition of RNA synthesis: Rifampicin is the main compound used clinically that 
acts against RNA synthesis. It's particular value is in the treatment of tuberculosis. It 
acts by inhibiting bacterial DNA-dependent RNA polymerase preventing RNA 
transcription and any subsequent translation. Rifampin binds noncovalently but 
strongly to a subunit of RNA polymerase and interferes specifically with the initiation 
process.  DNA-dependent RNA polymerase is a complex enzyme with an α2 β β‘ σ 
subunit structure. The binding site for rifampicin has been located at the β subunit 
encoded by the rpoB gene (Floss and Yu 2005).   Because it prevents the formation of 
mRNA, it effectively disrupts protein synthesis and thus its action is often 
bacteriostatic. However, it has no effect once polymerization has begun (Neu and 
Gootz 1996). 
 
Inhibition of protein synthesis: Enzymes and cellular structures are primarily made 
of proteins and, therefore, protein synthesis is an essential process necessary for the 
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multiplication and survival of all bacterial cells. Several antibiotics in these group act 
by binding to the 30S or 50S ribosomal RNA subunit preventing the binding of 
amino-acyl tRNA therefore inhibiting translation and normal cellular metabolism of 
the bacteria. Examples of antimicrobial agents that inhibit protein biosynthesis include 
aminoglycosides, macrolides, tetracyclines, chloramphenicol and lincomycins (Neu 
and Gootz 1996). 
 
Inhibition of cell wall synthesis: The composition of bacterial cell is unique in nature 
and drugs that target cell walls can therefore selectively kill or inhibit bacterial. 
Examples are β-lactam antibiotics, which inhibit transpeptidase and 
peptidoglycansynthesis preventing the cross linking of the polysaccharide chains in 
the bacterial cell wall. 
 
Inhibition of cell membrane function: A disruption or damage to cell membrane 
structure could result in leakage of important solutes essential for the cell’s survival. 
Polymyxins act by interacting with lipopolysaccharide destroying the outer and inner 
membranes. The hydrophobic tail is important in causing the damage suggesting a 
detergent like mode of action. 
 
Inhibition of metabolic pathway by acting on tetrahydrofolate synthesis: 
Sulphonamides and trimethoprim are the main compounds that act by inhibition of 
metabolic pathway. Sulphonamides are structural analogue of para amino benzoic 
acid (PABA) and compete with PABA. Sulphonamides competitively inhibit 
dihydropteroate synthetase resulting in the disruption of tetrahydrofolate synthetic 
pathway (Figure 1). It acts by blocking the conversion of pteridine and PABA to 
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dihydrofolic acid by the enzyme pteridine synthetase (Henry 1943). Trimethoprim 
inhibits dihydrofolate reductase, which is responsible for conversion of dihydrofolic 
to tetrahydrofolic acid leading to the synthesis of purines and ultimately DNA (Figure 
1). Dihydrofolate reductase is essential for folic acid biosynthesis and thus 
trimethoprim inhibit the utilization of folic acid by bacteria (Darrell et al. 1968). 
Trimethoprim and sulphonamides inhibit with folate metabolism in Gram-negative 
bacterial cell and act as folate antagonists. Tetrahydrofolate  is important for the 






Figure 1 Sites of action of Sulphonamide and Trimethoprim in folic acid 
biosynthesis. (adapted from Scholar and Pratt 2000) 
 
The figure show the site of action of sulphonamide and trimethoprim on the folic acid 
biosynthesis. Sulphonamide acts as a false substrate inhibitor of dihydropteroate  







1.5   β-Lactam antibiotics 
β-lactam antibiotics family are named and classified because of the presence of β-
lactam ring (Figure 2) which is a heteroatomic ring structure comprising of three 
carbon atoms and one nitrogen atom. 
Figure 2 Primary structure of Ampicillin with the β-lactam highlighted in red 
 
 
The figure shows the β-lactam ring, highlighted in red, which is a four membered 
lactam with  the nitrogen aton attached to the β-carbon relative to the carbonyl. 
 
   
The β-lactams act in the final step of cell wall synthesis in which strands of 
peptidoglycan are cross linked via peptide side chains. The β-lactam antibiotics block 
the transpeptidation of the cell wall component peptidoglycan, through inhibition of 
transpeptidases called penicillin binding proteins (PBP). The PBPs forms a covalent 
penicilloyl-enzyme complex  that blocks the transpeptidation which leads to 
irregularities in cell wall structure leading to cell lysis and eventually cell death 
(Wilke et al. 2005).   
 
The β-lactam antibiotics family include penicillins, cephalosporins, cephamycins, 
monobactams, β-lactamase inhibitor and carbapenems (Champoux et al. 2004). 
β-lactams show activity against Gram-negative and Gram-positives organisms, 
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including anaerobes. They are the most widely used class of antibiotics (Mims et al. 
2004). The cephalosporins are most often prescribed because of their broad spectrum 
of activity for more complicated and resistant infections. Due to increasing use of β-
lactams antibiotics, there is development of resistance due to production and 
dissemination of β-lactamases (Livermore 1998). β-lactamases are the most common 
cause of Gram-negative bacterial resistance to β-lactam antibiotics (Livermore 1995). 
It seems that the β-lactamases have been co-evolving with β-lactam antibiotics ever 
since it came into use (Medeiros 1997). Among β-lactams, carbapenems are 
antibiotics with a broad spectrum of antibacterial activity, compared to other β-
lactams such as penicillins and cephalosporins. A carbapenem is often used as a last 
resort drug to treat infections that are resistant to the cephalosporins. However 
carbapenems are attacked by few β-lactamases most notably the molecular class B 
enzyme (Livermore 1998). The attack to carbapenems has been reported to be caused 
by a combination of altered outer membrane protein, CTX-M-15 β-lactamases and 
upregulated efflux (Findlay et al. 2012). 
 
 
1.6 Development of Resistance 
 
Long before the discovery and use of antibiotics, bacteria where exhibiting resistance. 
This is largely because most antibiotics are produced by micro-organisms in the 
environment where bacteria encounter them naturally and develop a survival strategy. 
After the availability of antibiotics experts believed that infection would be a thing of 
the past, but Alexander Fleming was quoted in New York Times June 26, 1945 as 
saying “The greatest possibility of evil in self-medication is the use of too small doses 
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so that instead of clearing up infection the microbes are educated to resist penicillin 
and a host of penicillin-fast organisms is bred out which can be passed to other 
individuals and from them to others until they reach someone who gets a septicaemia 
or pneumonia which penicillin cannot save." In the early years of antibiotic 
development, bacteria resistance strains appear in hospitals where the antibiotics are 
used. Firstly, Streptococcus pyogenes resistant to sulphonamide appeared in military 
hospitals in 1930s (Delamater et al. 1946), Staphylococcus aureus resistant to 
penicillin appeared in the London hospitals after the introduction of the antibiotic in 
the 1940s (Barber and Rozwadowska-Dowzenko 1948). In a similar way soon after 
the discovery of streptomycin, Mycobacterium tuberculosis resistant to this antibiotic 
emerged in the community (Crofton and Mitchison 1948).From the review by  Levy 
and Marshall, multi-drug  resistance was first detected in Gram-negative bacteria-
namely Escherichia coli, Shigella and Salmonella spp.-in the late 1950s to early 
1960s (Levy and Marshall 2004). After the detection of resistant bacteria, the 
introduction of new antibiotics was used to prevent the damages caused by these 
bacteria.  This pattern of  introducing new antibiotics to counteract the resistance to 
previously-used drugs continued for almost all newly developed antibiotics. In recent 
years, however, the development of resistance appears to be outpacing the 
development of new antibiotics and is consequently resulting in the increasing 
emergence of multi-drug resistance (MDR) and Pan-drug resistance (PDR) strains 
(Levy and Marshall 2004).This is why treatment options are becoming limited and the 
pursuit of new antibiotics is of extreme importance. 
1.7 Mechanisms of Resistance 
 
Bacteria typically acquire resistance either through the ability of a gene in the 
bacterium to mutate or by the acquisition of resistance genes from other bacteria. 
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Several mechanisms have evolved in bacteria which confer resistance to antibiotics. 
These mechanisms include: drug inactivation or modification through the production 
of enzymes such as β-lactamases, alteration of the target site (PBP), alteration of a 
metabolic pathway, or reduced drug accumulation by efflux pump/decreased drug 
permeability (Figure 3) (Champoux et al. 2004). The most common mechanism is the 
enzymatic inactivation of the antibiotics. 
 
 
Figure 3 Mechanisms of resistance to Antibiotics: (modified from Coates et al. 
2002) 
 
This diagram shows the mechanism used by bacteria to confer resistance to antibiotics 
which includes inactivation of drug by bacteria enzymes,the activation of drug efflux 




1.7.1 Resistance to β-lactams 
 
Bacteria can avoid the bactericidal effect of β-lactam antibiotics by: active efflux 
pumps promoting the transport of the antibiotics out of the cell, alteration of the 
penicillin binding proteins (PBPs), lack/diminished expression of outer membrane 
proteins (OMPs) or finally production of β-lactamases that hydrolyses the β-lactam 
ring. 
1.7.1.1  Penicillin-binding protein 
 
 
PBP are the primary targets of β-lactam antibiotics. PBP catalyze an important step in 
bacterial cell wall synthesis [a transpeptidase reaction which removes a terminal 
alanine in a cross linking reaction with a nearby peptide]. There are several PBP 
mediated mechanisms of β-lactam resistance including acquisition of  a new less-
sensitive enzyme, a mutation of an endogenous PBP which lesses the reaction with 
the  β-lactam,while maintaining some transpeptidase activity or up regulation of PBP 
expression (Wilke et al. 2005). Alteration of the PBP so that the β-lactam antibiotics 
cannot bind to them is a principal resistance mechanism observed in Gram-positive 
bacterial species (Zapun et al. 2008). This alteration in the PBP is responsible for the  
emergence of methicillin resistance in Staphylococci aureus (MRSA) and penicillin 
resistance in pneumococci. The mecA gene which codes for an additional PBP in 
MRSA is present in the chromosome. It is important to note that the majority of the 
MRSA produce β-lactamase (Mims et al. 2004).  Although PBP alteration has be 
found in Gram-negatives (Zapun et al. 2008), their resistance to β-lactams is 




1.7.1.2 Outer membrane permeability 
 
The outer membrane of Gram negative bacteria play a vital role in providing 
protection as well as exchanging material required for sustaining life. The membrane 
is made up of a combination of hydrophobic lipids, lipopolysacharides and proteins 
(porins) acting as a selective barrier (Delcour 2009). Porins facilitate the transport of 
β-lactam antibiotic molecules across the cell membrane therefore loss of porins 
confers reduced susceptibility to these antibiotics. Loss or functional changes in 
porins contribute to the overall resistance associated with β–lactamase production. 
There are reports of porin deficiency contributing to β-lactam antibiotics resistance in 
organisms such as, Pseudomonas  aeruginosa, Enterobacter aerogenes, Neisseria 
gonorrhoeae, E. coli and Klebsiella pneumoniae (Crowley et al. 2002, Gayet et al. 
2003). In K. pneumoniae exhibiting resistance to carbapenem, the loss OmpK36 has 
been associated with carbapenem resistance (Kaczmarek et al. 2006). 
 
1.7.1.3  Efflux pump 
Expression of efflux pump is another mechanism involved in resistance to β-lactam 
antibiotics (Figure 3). Efflux pumps are proteins involved in the transport of toxic 
substrates and antibiotics across the cell membrane into the external environment.As 
reviewed by Poole, an efflux pump was first described as a mechanism of resistance 
to tetracycline in E. coli (Poole 2005) and since then efflux pumps have been 
implicated as the cause of antibiotic resistance within numerous clinically relevant 
bacteria species such as K. pneumoniae and Pseudomonas aeruginosa (Webber and 
Piddock 2003). Bacterial efflux systems capable of accommodating antimicrobial 
generally fall into five classes, the major facilitator (MF) superfamily, the ATP-
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binding cassette (ABC) family, the resistance-nodulation-division (RND) family, the 
small multidrug resistance (SMR) family [a member of the much larger 
drug/metabolite transporter (DMT) superfamily] and the multidrug and toxic 
compound extrusion (MATE) family (Poole 2005). The presence of efflux is often 
gauged in vitro with the use of efflux pump inhibitors such as Carbonyl cyanide m-
chlorophenylhydrazone (CCCP), Phenyl alanine arginyl b-naphtylamide (PABN) and 
reserpine. These efflux pump inhibitors are used alongside the relevant antibiotics to 
result in increased susceptibilities, when compared to the antibiotic alone, in the 
presence of active efflux.  
 
Efflux systems are able to confer resistance to a wide range of antibiotics and are 
common among Gram-negative bacteria. Decreased susceptibility due to efflux has 
been shown in P. aeruginosa to many class of antibiotics (Li et al. 1995), E. coli 
(Poole 2000), and Salmonella typhimurium, (Nikaido 2001)  Two of the most studies 
MDR efflux  are AcrAB-TolC of E. coli and the several Mex-Opr pumps of P. 
aeruginosa (Poole 2000).  Antibiotic efflux is mostly found to confer high level 
resistance in bacteria in association with other mechanisms such as β-lactamases. A 
good example is the cooperation between the penicillin efflux pumps and the β-
lactamases in Gram-negative bacteria showing a phenotype of high-level resistance 
without being high-level producers of β-lactamase (Masuda et al. 1999, Nakae et al. 
1999, Lakaye et al. 1999). It is important to note that high level resistance to 
antibiotics do not occur in the presence of efflux alone.  
1.7.2  Production of β-lactamases  
β-lactamases are the most important mechanism of resistance to β-lactam antibiotics. 
They are enzymes produced by many species of bacteria and were originally produced 
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to improve the chances of bacterium’s survival in the soil so it could competed with 
organisms producing β-lactam antibiotics. These enzymes are capable of conferring 
resistance to β -lactam antibiotics via the hydrolysis of the amide bond of β -lactam 
ring. The β-lactamases are classified by their protein sequence into four molecular 
classes A, B, C and D as shown in table 2.  These classes are split into two groups: 
those that contain a serine residue at their active site and those that require the metal 
ion, usually zinc, as a co-factor, known as metallo β-lactamases. Classes A, C, and D 
include enzymes that hydrolyze their substrates by forming an acyl enzyme through 
an active site serine, whereas class B β-lactamases are metalloenzymes that utilize at 
least one active-site zinc ion to facilitate β-lactam hydrolysis (Bush and Jacoby 







Table 2  β-lactamases classification schemes adapted from Bush and Jacoby 
(2010) 
 
Molecular class Bush-Jacoby group Distinctive substrates Representative enzymes 
A 2a Penicillin PC1 
 2b Penicillin, early cephalosporins TEM-1,TEM-2,SHV-1 
 2be Extended-spectrum 
cephalosporins, monobactams 
TEM-3, SHV-2, CTX-M-
15, PER-1, VEB-1 
 2br Penicillin TEM-30,SHV-10 
 2ber Extended-spectrum 
cephalosporins, monobactams 
TEM-50 
 2c Carbenicillin PSE-1 CARB-3 
 2ce Carbenicillin, cefepime RTG-4 
 2e Extended-spectrum cephalosporins CepA 
 2f Carbapenems KPC-2, IMI-1, SME-1 
B(B1) 3a Carbapenems IMP-1,VIM-1, CcrA, 
IND-1 
B(B3) L1,CAU-1,GOB-1,FEZ-1 
B 3b Carbapenems CphA, Sfh-1 
C 1 Cephalosporin AmpC, p99, ACT-1, 
CMY-2, FOX-1, MIR-1 
 1e Cephalosporin GC1, CMY-37 
D 2d Cloxacillin OXA-1 OXA-10 
 2de Extended-spectrum cephalosporins OXA-11OXA-15 
 2df Carbapenems OXA-23 OXA-48 




The table show the comparison of the different classification schemes of β-lactamases 
with the distictive substrates and representative enzymes. 
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1.8 The clinically most important β-lactamases 
1.8.1 Extended Spectrum β-Lactamases (ESBLs) 
ESBLs are β-lactamases that hydrolyze extended-spectrum cephalosporins with an 
oxyimino side chain. These cephalosporins include cefotaxime, ceftriaxone, and 
ceftazidime, as well as the oxyimino-monobactam, aztreonam. Thus ESBLs confer 
resistance to these antibiotics and related oxyimino-β-lactams. This extends the 
spectrum of β-lactam antibiotics susceptible to hydrolysis by these enzymes. Types of 
ESBLs include TEM, SHV, OXA, and CTX-M. Other plasmid-mediated ESBLs such 
as PER, VEB, GES, SFO and IBC β-lactamases have been described but are 
uncommon (Nordmann et al. 1993, Poirel et al. 1999, Poirel et al. 2000a, Matsumoto 
and Inoue 1999). An increasing number of ESBLs, not of TEM or SHV lineage, have 
been described. The ESBLs are frequently plasmid encoded usually alongside other 
resistance determinants (Paterson et al. 2003).  
 
Since the plasmid-mediated extended spectrum β-lactamases were first detected in a 
Klebsiella pneumoniae isolate in 1983 in Germany (Kliebe et al. 1985), they have 
been increasingly reported worldwide (Bradford 2001).The classical ESBLs are those 
derived from the broad spectrum enzyme TEM-1,TEM-2 and SHV-1 by the 
acquisition of specific point mutations which expand their spectrum of hydrolysis to 
oxyimino-cephalosporins and aztreonam (Bush et al. 1995). Nevertheless, the most 
wide spread plasmid-mediated ESBLs nowadays are variations of CTX-M enzymes 
(reviewed by (Canton et al. 2012) and will be further discussed . Most of the ESBLs 
are found in Gram-negative organisms including Klebsiella spp., E. coli, P. 
aeruginosa, Enterobacter spp. and Salmonella spp. (Bradford 2001). 
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1.8.1.1 TEM  
The ESBLs family TEM named after a patient Temoniera was first reported in 1965 
from an E .coli isolate (Datta and Kontomichalou 1965). The TEM-l β-lactamase, 
which is not an ESBL, is able to hydrolyse ampicillin and early cephalosporins such 
as cephalothin and cephaloridine. Because of its location in the plasmid, TEM-1 
spread worldwide and can be found in many different members of the family 
Enterobacteriaceae (Bradford 2001). The TEM-2 β-lactamase is the first derivative of 
TEM-1 but is still not considered an ESBL having a substrate profile identical to 
TEM-1. TEM-2 had a single amino acid substitution at position 39 (Gln39→Lys) 
from the original TEM-1 β-lactamase. TEM-3 first isolated from Klebsiella 
pneumonia in 1987, is the first TEM-β-lactamase to display the ESBL phenotype 
(Sirot et al. 1987). The sequence of TEM-3 shows that it is related to TEM-2 with the 
difference in two amino acid changes at position 104 (Lys→Glu) and 238 (Ser→Gly) 
(Sougakoff et al. 1988). TEM-3 has an unusual resistance phenotype towards 
cefotaxime which is not shown in TEM-1 and -2. The mutation at position Gly238 
with serine is critical for altering substrate specificity for cefotaxime hydrolysis 
(Cantu and Palzkill 1998).  There are a number of amino acid residues especially 
important for producing the ESBL phenotype and extending its hydrolytic spectrum. 
They include amino acid substitutions at: glutamate to lysine at position 104, arginine 
to either serine or histidine at position 164, glycine to serine at position 238, and 
glutamate to lysine at position 240 (Bradford 2001). Currently, 190 TEM type β-




The acronym SHV refers to Sulfhydryl Variable designated because it was thought 
that SHV hydrolysed cephaloridine but not benzylpenicillin in the presence of 
p-chloromecuribenzoate inhibitory binding chemical (Tzouvelekis and Bonomo 
1999). The SHV-1 β-lactamase was first described in 1972 (Pitton 1972) and confers 
resistance to ampicillin, amoxicillin, carbenicillin, ticarcillin. SHV-1 share 68% 
amino acid similarity with TEM-1 and has similar tertiary structure. The majority of 
SHV variants possessing an ESBL phenotype are characterized by the substitution of 
a serine for glycine at position 238. A number of variants related to SHV-5 also have 
a substitution of lysine for glutamate at position 240. It is interesting to note that both 
the Gly238Ser and Glu240Lys amino acid substitutions mirror those seen in TEM-
type ESBLs (Bradford 2001). Both Gly238Ser and Glu240Lys amino acid 
substitutions is needed for strong hydrolysis of ceftazidime where as Gly238Ser is 
critical for cefotaxime hydrolysis (Huletsky et al. 1993).  SHV type ESBL are found 
mostly in strains of K. pneumoniae but these enzymes has been found in other Gram-
negative bacteria including E. coli, as plasmid mediated β-lactamases (Sabaté et al. 
2002). Currently over 130 variants of SHV are known. 
 
1.8.1.3 OXA 
This β-lactamase differ from TEM and SHV in that they belong to molecular class D 
and functional group 2d (Bush et al. 1995). They have the ability to hydrolyse and 
confer resistance to cloxacillin and penicillin. blaOXA genes comprise the 
chromosomal β-lactamases of Acinetobacter spp, known as OXA-51-like (Evans et 
al. 2007).. Some of these genes have migrated out of Acinetobacter spp into P. 
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aeruginosa and to a lesser extent into members of the Enterobacteriaceae including E. 
coli and K. pneumoniae (Naas and Nordmann 1999). These transfers have occurred on 
plasmids and outside Acinetobacter spp, blaOXA genes are almost invariably plasmid-
encoded.  
 
The OXA ESBLs were originally isolated in P. aeruginosa isolates from a hospital in 
Ankara, Turkey (Hall et al. 1993). Currently OXA ESBLs are derived from the OXA-
1,-10, and -2 β-lactamases. Among the enzymes related to the OXA-10 β-lactamase, 
there are one or two amino acid substitutions: an asparagine substitution for serine at 
position 73, or an aspartate substitution for glycine at position 157. In particular, the 
Gly157Asp substitution may be necessary for high-level resistance to ceftazidime 
(Bradford 2001). There are currently over 200 OXA gene derivatives, 16 of which are 
ESBLs derived from OXA-2 and OXA-10 (www.lahey.org/studies/webt.asp.).  
 
 
1.8.1.4       CTX-M β-lactamases 
 
The name ‘CTX-M’ is an abbreviation for ‘cefotaximases’ and refers to the more 
potent hydrolytic activity of these enzymes against cefotaxime than other oxyimino-β-
lactam substrates. However, CTX-M enzymes that are able to hydrolyze ceftazidime 
efficiently have also been describe (Bonnet 2004). CTX-M enzymes are distinct class 
of ESBLs, which arose by gene escape from genus Kluyvera, (Canton 2008) which is 
closely related to E. coli. CTX-M-type β-lactamases constitute a group of class A 
plasmid-encoded enzymes, which are capable of hydrolyzing broad-spectrum 
cephalosporins and are inhibited by clavulanate and tazobactam. In that respect, CTX-
M-type enzymes are typical ESBLs and have therefore been classified in the 
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functional group 2be of the Bush, Jacoby and Medeiros classification scheme (Table 
2), which also contains the Extended Spectrum derivatives of TEM-1/2 and SHV-1 β-
lactamases (Bush et al. 1995).  
 
 
Figure 4: Dendrogram of the CTX-M gene clusters 
 
This dendrogram shows the relative distances between the primary amino acid 






Unlike the TEM and SHV enzymes, the CTX-M enzymes have not evolved from 
point mutations from the parent strain rather they originate from chromosomal bla 
gene of Kluyvera spp (Bonnet 2004). Subsequently, mutation has contributed to the 
diversification of the CTX-M family. CTX-M β-lactamases were cefotaximases but 
these subsequent mutations gave rise to expanded hydrolytic activity to ceftazidime. 
An example is the CTX-M-15 which was derived from CTX-M-3 by Asp240→Gly 
substitution which increases the catalytic activity to Ceftazidime (Poirel et al. 2002a) .  
Currently more CTX-Ms are able to hydrolyse both cefotaxime and ceftazidime. 
 
The CTX-M groups are sub-classified by amino acid similarities into five different: 
CTX-M-1 group, CTX-M-2 group, CTX-M-9 group, CTX-M-8 group and CTX-M-25 
group. The members of each group share 94% amino acid sequence similarities and 
90% similarities between groups. CTX-M β-lactamase is natural in the chromosome 
of Kluyvera cryocrescens, Kluyvera ascorbata, and Kluyvera georgiana (Bonnet 
2004). blakluC gene from Kluyvera cryocrescens is considered the ancestor for CTX-
M-1 group (Decousser et al. 2001), blakluA from Kluyvera ascorbata for CTX-M-2 
group (Humeniuk et al. 2002). There are three genes present in Kluyvera georgiana 
designated blaKluG,  blaKluY, and  blaCTX-M-78. blaKluG, is considered the origin of CTX-
M- 8,(Poirel et al. 2002b) blaKluY for CTX-M-9 cluster (Olson et al. 2005) and blaCTX-
M-78 for CTX-M-25 cluster (Margarita Rodriguez et al. 2010). This suggests the 
mobilisation of this type of β-lactamase from the chromosome to the plasmids. Thus 
CTX-M β-lactamases originated from Kluyvera Spp chromosomal gene. Over 130 
different variant of CTX-M have been described so far 
(www.Lahey.org/studies/webt.asp - last accessed 3 December 2012).   
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1.8.1.4.1 CTX-M Emergence 
 
Matsumoto et al reported in 1988 a non-TEM, non-SHV ESBL, designated FEC-1, in 
a cefotaxime-resistant Escherichia coli strain isolated from the faecal flora of a 
laboratory dog, which was used for pharmacokinetic studies of β-lactam antibiotics in 
Japan (Matsumoto et al. 1988). A few years later, CTX-M-1 in reference to its 
hydrolytic activity against cefotaxime was first detected from an Escherichia coli 
strain in 1989 in Germany (Bauernfeind et al. 1990). At the same time in 1990, an 
explosive dissemination of a cefotaxime-resistant Salmonella strain began in 
Argentina which was plasmid mediated named CTX-M-2 (Bauernfeind et al. 1992). 
The β-lactamases responsible for the resistance to cefotaxime observed in Argentina 
had alkaline pI values, conferred a high level of resistance to cefotaxime rather than 
ceftazidime and were susceptible to the inhibitors sulbactam, clavulanic acid and 
tazobactam. In 1992, the same type of ESBL, designated MEN-1, was reported in a 
clinical E. coli strain MEN, isolated in 1989 in France from a patient hospitalised at 
French anti-cancer centre, who was an Italian national (Bernard et al. 1992). A few 
years later, there was a report of a MEN-1 related enzyme, designated Toho-1, which 
was produced by a cefotaxime-resistant E. coli strain isolated in 1993 in Japan (Ishii 
et al. 1995). Analysis of the sequences of the two non-TEM, non-SHV ESBL-
encoding genes revealed that CTX-M-1 was identical to MEN-1 and is a variant of 
Toho-1 (Bauernfeind et al. 1996).  
 
Subsequently in Poland, a report emerged of a variant of CTX-M-1, designated CTX-
M-3, in different members of the family Enterobacteriaceae isolated in 1996 
(Gniadkowski et al. 1998). Since then, CTX-M enzyme have formed a rapidly 
growing family of ESBLs distributed both over wide geographic areas and among a 
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wide range of clinical bacteria, in particular, member of the family of 
Enterobacteriaceae (Canton et al. 2012).  
 
There has been a dramatic increase in the number of organisms reported in the 
literature that produce CTX-M β-lactamases. This class of β-lactamases has been 
recognised worldwide as an important mechanism of resistance to oxyimino 
cephalosporin used against Gram-negative pathogens. In most cases, the bacteria 
producing these enzymes display higher levels of resistance to cefotaxime and 
cefriaxone than ceftazidime (Bonnet 2004). However some point mutations produced 
enzymes with a much stronger activity against ceftazidime. For instance, CTX-M-15 
was derived from CTX-M-3 by an Asp-240→Gly substitution which increased the 
catalytic activity of Ceftazidime (Poirel et al. 2002a). The Asp-240→Gly substitution 
were also observed in CTX-M-16 and CTX-M-27 also presenting a high catalytic 
activity against Ceftazidime (Bonnet et al. 2001).Also responsible for increased 
ceftazidime resistance  is the Pro-167→Ser mutation which differentiates CTX-M-9 
from CTX-M-14 (Poirel et al. 2001). 
 
The CTX-M-15 and CTX-M-14 are the most important CTX-M enzymes which can 
be found in human, animal as well as in the environment all over the globe (Canton et 
al. 2008, Hawkey and Jones 2009, Dolejska et al. 2011, Hiroi et al. 2012). CTX-M-15 
was first described in 1999 from enteric isolates recovered from a hospital in New 
Delhi India (Karim et al. 2001). However a retrospective study in Poland showed the 
presence of CTX-M-15 in E.coli and Serratia marcescens before the first description 
of this enzyme in India with sequence and plasmid analysis revealing a potential 
26 
 
evolution from CTX-M-3 (Baraniak et al. 2002). Currently CTX-M-15 is found to 
have  disseminated all over the world (Canton et al. 2012). 
 
CTX-M-14 was first reported in 2001 from an isolate obtained in 1996 from a stool 
isolate of Shigella sonnei,and blood isolates of Escherichia coli and Klebsiella 
pneumoniae from different parts of Korea (Pai et al. 2001). This was followed by a 
rapid dissemination all over the world including China (Chanawong et al. 2002), 
Taiwan (Yu et al. 2002) and France (Dutour et al. 2002) 
 
Highly transmissible plasmids often encode CTX-M enzymes and enable the gene to 
be transferred from one species to another and one genus to another. The blaCTX-M 
genes are encoded in the plasmids belonging to the narrow host range incompatibility 
types (IncF1, IncFII, IncH12 and IncI) or the broad host range incompatibility types 
(IncN, IncP1, IncL/M and IncA/C) (Novais et al. 2007, Carattoli 2009, Coque et al. 
2008b).   
 
1.8.1.4.2 Prevalence of CTX-M among Enterobacteriaceae in UK    
 
Antimicrobial resistance among Enterobacteriaceae has become a growing problem 
in the UK. In the UK isolation of CTX-M was rare before 2001. Several papers have 
reported the growing incidence of ESBLs among Enterobacteriaceae in the UK, not 
least those of the CTX-M-like genotype (Livermore and Hawkey 2005, Woodford et 
al. 2007).The most prevalent CTX-M members among all the reported cases in the 
UK are CTX-M-14 and CTX-M-15 although CTX-M-26 and CTX-M-9 have also 




However, the first CTX-M identified in UK was from a clinical isolate of Klebsiella 
oxytoca recovered from a stool sample of a 6-year-old child in May 2000, producing 
CTX-M-9 (Alobwede et al. 2003). This was followed, in 2001 by an outbreak in a 
Birmingham hospital, involving 30 patients and caused by a Klebsiella pneumoniae 
strain with CTX-M-26 β-lactamases (Brenwald et al. 2003). Also in 2001, a survey by 
Mushtaq et al examined over 200 Enterobacteriaceae from 26 hospitals in the UK 
and Ireland and recorded four isolates with CTX-M-15 enzyme (Mushtaq et al. 2003). 
A study in 2003 at York, UK showed that out of 22 ESBL positive 
Enterobacteriaceae isolates, 17 strains were positive for CTX-M (Munday et al. 
2004a). In late 2004, a prospective survey was undertaken covering 16 laboratories in 
London (8) and SouthEast England (8) seeking up to 100 Enterobacteriaceae per site. 
This yielded 1122 out of 1253 isolates with confirmed cephalosporin resistance out of 
which 502 (44.7%) carried a CTX-M enzyme (Potz et al. 2006). Furthermore, a report 
in 2007 also found that out of 33 E. coli, 23 possessed blaCTX-M-15, which were 
genetically linked to ISEcp1(Tarrant et al. 2007). 
 
The rapid emergence of the CTX-M as the predominant ESBL type in the UK is not 
an isolated occurence. A report on ESBL types in Enterobacteriaceae in Argentina 
found that CTX-M accounted for roughly 54% of all ESBLs found in that country 
(Quinteros et al. 2003). Similarly studies in Japan, China, Taiwan and Spain showed 
the same high incidence of CTX-M ESBLs (Yamasaki et al. 2003, Yu et al. 2002, 
Canton et al. 2002, Munday et al. 2004b). The CTX-M-1 group enzyme mainly CTX-
M-15 accounted for most CTX-M β-lactamases found in the UK followed by CTX-
M-9 group, mainly CTX-M-9 and to a lesser extent CTX-M-14. 
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(Mushtaq et al. 2003, Woodford et al. 2004, Dimude and Amyes 2013).  The CTX-M-
15 isolates from the UK were particularly associated with the E.coli clone A to F with 
clone A later identified as belonging to O25:H4-ST131 clone - that has been isolated 
all over the world (Clermont et al. 2008, Coque et al. 2008b, Lau et al. 2008b, Lau et 
al. 2008a). Over the years in the UK CTX-M enzymes has been detected in isolates 
from hospitalised patients, patients in the community and from animals - with CTX-
M-15 being the most prevalent (Dhanji et al. 2011, Younes et al. 2011, Woodford et 
al. 2004, Horton et al. 2011).  
 
Furthermore most of the CTX-M producers are found also to be resistant to the  
fluoroquinolones, with the resistance found to be associated with the new variant of 
aminoglycoside modifying enzyme aac(6’)-Ib-cr (Machado et al. 2006, Cerquetti et 
al. 2010). There is an observation of a strong relationship between blaCTX-M-15 and aac 
(6’)-Ib-cr in the same strain. This led to the study of this relationship by Jones et al in 
UK strains which shows that aac(6’)-Ib-cr occured in the UK preceding the 
acquisition of blaCTX-M-15 (Jones et al. 2008). 
1.8.1.4.3 Prevalence of CTX-M in Egypt 
 
Before the first detection of CTX-M in Egypt, there has been reports of a high 
proportion of  ESBLs in E.coli (El Kholy et al. 2003, Borg et al. 2008). The presence 
of CTX-M-15 was reported in 2006, which found  28 ESBL- producing E.coli isolates 
having  a CTX-M type gene (Mohamed Al-Agamy et al. 2006). Among the 28 CTX-
M isolates 18 were found to harbour blaCTX-M-15, 7 harboured blaCTX-M-27  and 3 had 
blaCTX-M-14.  At the time of this finding there was no information present on the spread 
of CTX-M in Egypt with the author expressing that it’s not unlikely that these strains 
producing CTX-M could spread in a population where antibiotics are available 
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without prescription. This study was followed by the first report of CTX-M-14 in K. 
pneumonia and Ent. cloacae (Khalaf et al. 2009). A more thorough epidemiological 
study on both isolates from the hospital and community setting in 2010 found 74 
isolates with blaCTX-M-15 gene out of the 83 ESBLs producers showing a high 
proportion of this gene (Fam et al. 2011). At the same time a report of plasmid 
mediated CTX-M-14 in Salmonella serovar Typhimurium was reported from Egypt 
(AbdelGhani et al. 2010).  The data from Egypt is not surprising because 
antimicrobial can be purchased without prescription leading to misuse likely to 
encourage the selection of resistant strains. 
 
1.8.2 Carbapenemases 
Carbapenemases are capable of hydrolysing not only the cephalosporins and 
oxyimino-cephalosporins but also the carbapenem antibiotics. The carbapenemases 
are the group of β-lactamases that are of great concern in Gram-negative bacteria 
because the carbapenem antibiotics are the last mainstream drugs of resort for the 
treatment of MDR infection caused by Gram-negative bacteria. The carbapenamases 
can be found within each of the four molecular classes of β-lactamases. The molecular 
class A carbapenemases include the plasmid mediated Klebsiella pneumoniae 
carbapenemase (KPC), the Guiana extended spectrum (GES), the chromosomally 
encoded Serratia marcescens enzyme (SME), the related NMC carbapenemases and 
the imipenem-hydrolysing (IMI) β-lactamases 
 
The molecular class B Metallo β-lactamases (MBL) includes: active on imipenem 
(IMP) (Watanabe et al. 1991), Verona integron-encoded metallo-β-lactamase (VIM) 
(Lauretti et al. 1999), Sao Paulo metallo-β-lactamase (SPM) (Toleman et al. 2002), 
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Seoul imipenemase (SIM) (Lee et al. 2005), German imipenemase (GIM) 
(Castanheira et al. 2004) and New Delhi MBL (NDM) (Yong et al. 2009). 
 
The molecular class C is the CMY-10 type first isolated from Enterobacter aerogenes 
in 2003 and one of only a few that belongs to β-lactamase molecular class C (S. H. 
Lee et al. 2003). However, the CTX-M-15 β-lactamases has also been identified as 
having carbpanemase activity (Findlay et al. 2012).  Resistance to carbapenem by 
CTX-M producing Enterobacteriaceae has been reported with a combination of other 
resistance mechanisms such as selection of mutations leading to lack of porin 
expression, upregulated efflux or OMP alteration (Mena et al. 2006, Oteo et al. 
2008).These resistance mechanism cannot confer resistance to carbapenem on its own 
but can result in resistance together CTX-M enzymes. The molecular class D 
carbpanemases are the Oxacillinase OXA enzyme type. They are mainly found in 
found in Acinetobacter baumannii (reviewed by (Evans et al. 2007) and P.aeruginosa 
(Kong et al. 2005). 
 
1.8.2.1 VIM β-lactamases 
VIM is a second growing family of MBL apart from IMP. VIM-1 metallo β-
lactamases was first reported in Verona Italy from an isolate of P.aeruginosa in 1997 
(Lauretti et al. 1999). The VIM-1 β-lactamase shares less than 30% amino acid 
similarities with the IMP group of transferable carbapenemases that are largely 
confined to Japan: however, it is more closely related to BCll from B. cereus sharing 
39% amino acid identity(Lauretti et al. 1999). blaVIM genes are found as part of the 
gene cassette inserted into an integron in addition to an aacA4 gene cassette encoding 
resistance to the aminoglycosides. Shortly after the identification of VIM-1 β-
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lactamase, a closely related β-lactamase, VIM-2, was isolated in the south of France 
from a P. aeruginosa isolated from a blood culture taken from a neutropenic patient in 
1996 (Poirel et al. 2000b). VIM-2 shares 90% amino acid similarity the VIM-1 β-
lactamase and is also encoded in an integron. There is usually a sulphonamide 
resistance gene found in the 3΄element of the integron. Subsequently, VIM-2 
producing P. aeruginosa isolates were found to be associated with outbreaks in 
hospitals in Italy and Greece (Lagatolla et al. 2004, Pournaras et al. 2003). 
Identification of the VIM-3 β-lactamase in P. aeruginosa from Taiwan showed the 
amino acid sequence differed from that of VIM-2 by two amino acid changes (Yan et 
al. 2001).This was the first identification of VIM outside Europe indicating 
worldwide spread of this β-lactamase group. 
 
1.8.3 Resistance to trimethoprim- sulphamethoxazole  
Resistance to trimethoprim is mediated with the acquisition of dhfr genes (Amyes and 
Smith 1974) while resistance to sulphonamides is mediated with the acquisition of sul 
genes (Skold 1976). The prevalence of resistance to trimethoprim-sulphamethoxazole 
in Gram-negative bacteria is high (Huovinen 2001). The sulphonamide resistance 
gene sul is often found be fused to the qac gene in the 3΄conserved segment of 
integrons (Stokes and Hall 1989). Similarly the dhfr gene coding for trimethoprim 
resistance is often found as gene cassette in the variable region of integron (Partridge 
et al. 2009). Integrons are very common in multi drug resistance Gram-negative 
bacteria (Byarugaba 2010). Use of sulphamethoxazole in combination with 
trimethoprim is shown to have a synergistic effect with the first description both in 




1.8.4 Resistance to Aminoglycosides 
Bacteria continually develop a variety of mechanisms to evade the lethal effect of 
antibiotics. Resistance to aminoglycosides is usually causes by Aminoglycoside 
Modifying Enzymes (AME) that render the aminoglycosides incapable of binding to 
its ribosomal target (Reviewed by Ramirez and Tolmasky 2010). The AME enzymes 
inactivate aminoglycosides by transferring a functional group to the aminoglycoside 
structure. This makes the aminoglycoside unable to interact with the ribosome 
effectively. All of the major classes of enzymes conferring resistance to amino-
glycosides have been described, these include: acetyltransferases, 
nucleotidyltransferases, and phosphotransferases (Shaw et al. 1993). These amino 
acid modifying enzymes are often located on the plasmids or transposons with other 
resistance genes encoding resistance to other classes of antibacterials. Consequently 
the consumption of non-aminoglycoside antibiotics can influence the epidemiology of 
aminoglycoside resistance. The presence of these genes on mobile genetic elements 
facilitates their dissemination into various bacteria populations. All these enzymes 
conferring resistance to aminoglycosides have been described in Gram-negative 
bacteria (Davies and Wright 1997, Mingeot-Leclercq et al. 1999, Kettner et al. 1981, 
Kallova et al. 1997, Dornbusch et al. 1990, Vatopoulos et al. 1992). 
1.9 Mechanisms of dissemination of resistance genes. 
Antibiotic resistance in bacteria has been spreading and evolving in a complex 
process involving a variety of mechanisms. There are different ways in which 
dissemination of resistance gene can occur such as: clonal spread, plasmids or mobile 
genetic elements (reviewed by Courvalin, 2005). Mobile genetic elements (MGEs) are 
segments of DNA that encode enzymes and other proteins that mediate the movement 
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of DNA within genomes (intracellular mobility) or between bacterial cells 
(intercellular mobility) (Frost et al. 2005). There are two main categories of mobile 
genetic elements: elements that can move from one bacterial cell to another, namely 
plasmids and bacteriophages; and those that can move from one genetic location to 
another within the same cell- such as transposons ,integrons, insertion sequence 
common region (ISCR)-promoted gene mobilisation (Bennett 2008). 
 
1.9.1 Plasmids 
Plasmids are transferable genetic elements capable of self replication within a suitable 
host. Bacterial plasmids can act as a scaffold upon which gene arrays can be built, 
often encoding antibiotic resistance genes, by the incorporation of transposable 
elements and integron gene cassettes. A resistance plasmid is one which encodes 
resistance genes to one or more antibiotics (Bennett 2008). Many of the resistance 
plasmids encode the functions necessary to promote cell-to-cell DNA transfer which 
can be attributed to the global dissemination of plasmid mediated CTX-Ms among 
Gram-negative bacteria. CTX-Ms have been described on plasmids, most especially 
CTX-M-15 (Dimude and Amyes 2013, Naseer et al. 2009, Woodford et al. 2009). 
Plasmid replicon typing has identified different replicon types associated with specific 
blaCTX-M. It has been observed that blaCTX-M-15 is associated with incompatibility group 
IncFII plasmids with in some cases also found on multireplicon plasmids harbouring 
additional FIA and FIB (Coque et al. 2008b, Novais et al. 2007, Hopkins et al. 2006). 
On the other hand a  broad range of replicon plasmids such as IncN (Shen et al. 2008), 
IncL/M (Naas et al. 2011), IncK (Valverde et al. 2009), IncH12 (Garcia Fernandez et 
al. 2007) and IncI1 (Woodford et al. 2009) have all been involved in the 




Transposons, also known as ‘jumping genes’, are elements that can move from one 
location on the genome to another by transposition. A transposon contains a number 
of genes coding for antibiotic resistance, flanked on both sides by insertion sequences 
(IS) encoding a transposase enzyme. The transposase can be found in both Gram-
positive and Gram-negative bacteria and are identified by the presence of inverted 
repeated sequences at both ends of the element. Transposons are an essential 
mechanism in bacteria responsible for the dissemination of antibiotics resistance 
genes. CTX-M genes have been found to be associated with transposons such as Tn2 
(Roy Chowdhury et al. 2011), Tn2051 (Potron et al. 2012) Tn402 (Novais et al. 
2006), and Tn21 (Valverde et al. 2006).Transposons carrying antibiotic resistance 
genes have the ability to enter either a conjugative plasmid or chromosome (Norman 
et al. 2009).  
 
1.9.3 Insertion sequence 
Insertion sequences are small genetic elements flanked by short terminal inverted-
repeat sequence (IR) of 10-40bp and are able to insert at multiple sites in target DNA 
(Mahillon and Chandler 1998). Insertion sequences carry the information necessary 
for insertion functions but do not carry any accessory genes, such as antibiotic 
resistance genes. Insertion sequences play a role in the expression of blaCTX-M gene in 
Gram-negative bacteria. ISEcp1 has been found upstream of blaCTX-M genes and has 
been shown to be involved in dissemination and over-expression of the gene leading 
to cephalosporin resistance (Poirel et al. 2003, Eckert et al. 2006, Saladin et al. 2002). 
The presence of insertion sequence IS903 downstream of blaCTX-M genes has been 
35 
 
reported in several papers (Pai et al. 2001, Lartigue et al. 2004, Chanawong et al. 
2002). Analysis of the promoter region in bacteria producing plasmid mediated β-
lactamases revealed insertion elements IS26, IS903, ISEcp1 and these elements could 
play an important role in dissemination and selection of such ESBLs (Eckert et al. 
2006). ISEcp1 mobilizes genes by transposing adjacent to them, and then misreading 
one of its cognate ends in a second transposition event, with the effect of moving the 
adjacent gene. This process has been carried out experimentally for CTX-M gene 
from chromosome of Kluyvera spp. (Lartigue et al. 2006). 
 
In addition the same blaCTX-M has been found to be linked to the insertion sequence 
common region 1(ISCR1formerly orf513) upstream of the gene (Di Conza et al. 2002, 
Eckert et al. 2006). The ISCR1 is found at 3’CS on a class 1 integron suggesting 
participation in gene mobilisation by a rolling circle replication in addition to 
providing a putative promoter for high level expression.(Rodriguez-Martinez et al. 
2006, Toleman et al. 2006) 
1.9.4 Integrons and gene cassettes 
Integrons are DNA elements with the ability to capture genes by site specific 
recombination and are not self transmissible. Integrons contain an integrase gene (intl) 
to mediate the excision and integration of DNA into the integron. Integrons often 
reside within transposons and so represent a mechanism by which new antibiotic 
resistance genes are added to the complement of a transposon and are subsequently 





Figure 5  Integron may be inserted into transposons (taken from Norman et al. 
2009)  
The figure show how integron with resistance gene cassete may be inserted into the 
transposon and subsequently to a conjugative plasmid which can be disseminated 
between bacteria. 
 
All integrons characterised to date have these essential components: the intl gene 
encoding an integrase belonging to the tyrosine-recombinase gene family. In the 
integron there is a recombination site att , which is recognised by the integrase (Figure 
5) and is a receptor site for incoming gene cassettes, as well as an outward oriented  
promoter(Pc), which  transcribes the inserted gene cassettes (Mazel 2006). Currently, 
five classes of mobile integrons are known to have a role in the dissemination of 
antibiotic resistance genes. These classes have been defined based on the sequence of 
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the encoded integrases, which show 40–58% identity between themselves (Mazel 
2006). There are three separate classes of integron involved in antibiotic resistance, 
designated class 1, class 2 and class 3 (reviewed by (Cambray et al. 2010).  
 
Figure 6 Functional platform of an integron (Cambray et al. 2010) 
 
The figure show the general structure of an integron with the integrase gene Intl , the 
promoter region and the gene cassettes. 
 
Class 1 integrons were first described by Stokes and Hall (Stokes and Hall 1989). This 
class of integron is associated with functional and non-functional transposons derived 
from transposon Tn402 that can be embedded in larger transposons, such as Tn21 
(Mazel 2006). Class 1 integrons are found extensively in clinical isolates, and the 
majority of known antibiotic resistance gene cassettes belong to this class. Over 80 
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different gene cassettes, which form this class, have been described which confer 
resistance to β-lactams, all aminoglycosides, chloramphenicol, trimethoprim, 
streptothricin, rifampicin, erythromycin, fosfomycin, lincomycin and antiseptics of 
the quaternary-ammonium-compound family (Rowe-Magnus and Mazel 2002, Fluit 
and Schmitz 2004). The class I integrons are also characterised by the 5΄ and distal 
3΄CS conserved segment (CS). The 3΄CS often consists of qacEΔ1 gene, which 
represents a truncated version of the gene cassette qacE, which encodes resistance to 
quaternary ammonium compounds, the sul1sulphonamide resistance determinant and 
ORF6, which has no known biological function. 
 
Class 2 integrons are found to be associated with Tn7 derivatives and, in contrast, to 
class 1 integrons, only six different resistance cassettes have been found associated 
with them (Ramirez et al. 2005, Biskri and Mazel 2003). This can be attributed to the 
fact that the gene encoding the integrase in class 2 integrons contains a nonsense 
mutation in codon 179 (ochre 179), thereby yielding a truncated, non-functional 
protein (Hansson et al. 2002). 
 
Class 3 integrons are thought to be located on a transposon inserted on an, as yet, 
uncharacterised plasmid (Mazel 2006). Class 3 integrons were first described in Japan 
(Arakawa et al. 1995) and have been involved in antibiotic resistance in clinical 
isolates from Portugal and Canada (Arakawa et al. 1995, Xu et al. 2007, Correia et al. 
2003). 
 
The other two classes of mobile integrons, class 4 and class 5 have been described in 
Vibrio cholerae and Vibrio salmonicida respectively (Mazel 2006). It is interesting to 
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note that all these classes of integron have been found in Gram-negative bacteria as a 
means of dissemination of antibiotics resistance genes. 
 
1.10 Antibiotic resistance in Gram-negative organisms: 
combating resistance and surveillance 
Gram-negative bacteria are among the most important cause of serious infection in 
humans and antibiotic resistance in this group of pathogens has become an 
increasingly health problem worldwide (Hawkey and Jones 2009). Antibiotic 
resistance is now considered a global health problem that increases morbidity, 
mortality and treat infectious disease (Livermore 2009, Hawkey and Jones 2009). 
Specifically antibiotic resistance leads to longer hospital stays, increased  exposure of 
others to drug-resistant isolates, and therefore to higher hospital costs, when compared 
with infections associated with susceptible isolates. β-lactam antibiotics are arguably 
the most important antibiotic class used in the treatment of infection caused by Gram-
negative bacteria. There have been reported cases of resistance against β-lactam 
antibiotics in Gram-negatives (Rahal 2009).  
 
Initialising steps towards combating the rise of resistance must include but not limited 
to surveillance to provide information necessary for the management of these 
pathogens to minimise morbidity and mortality. Surveillance studies on antibiotic 
resistance allow us to gather information regarding: 1) existing trends in pathogen 
incidence and antibiotic resistance mechanisms; 2) the appearance of novel resistance 




Furthermore infection control measures are vital to help prevent transmission and 
persistence of bacteria in general and MDR bacteria specifically within the hospital 
environment and larger community. Health care professionals should be made aware 
of important infection control measures such as reduced patient contact and 
appropriate hand-hygiene can be, and there is evidence for such measures successfully 
controlling outbreaks (Enoch et al. 2008). The combined use of alcohol-based hand 
gels and improved infection control education are expected to and have limited the 
spread of nosocomial infections. 
 
Additionally, the large scale spread of resistance to antibiotics has been attributed, at 
least in part, to the inappropriate prescribing and administration of antibiotics 
(Goossens et al. 2005, Goossens 2009). A more rational and controlled use of 
antibiotics is required to reduce the selective pressure that they provide. In order to 
combat this health authorities have introduced antibiotic prescription guidelines 
alongside continuous monitoring of infections and resistance in order to detect the 
early development of any patterns of what so that appropriate interventions can be put 
in place to limit their spread. Continual non-sensational education is important to 
maintain and increase public awareness of the issues, and encourage both patients and 
clinicians against the misuse of antibiotics. 
 
Above all increasing our understanding of bacterial resistance development,is 
essential to pinpoint new targets for antibiotic agents. It is also vital to enable the 
implementation of effective methods to slow the seemingly relentless rise of 
resistance, and to warn against the development of  potential new resistance 
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mechanisms. All these when used in conjunction with one another will help developed 
a strategy to protect the public health both now and in the future. 
 
1.11 Bacteria species investigated  
1.11.1 Escherichia coli 
Escherichia coli is named after the original discoverer Theodor Escherich.  E. coli are 
facultative anaerobic, Gram-negative rods which are motile and may appear with or 
without a capsule. Most strains of E.coli ferment lactose with the production of acid 
and gas within 24-48 hours, while some do so only after extended incubation or are 
non- lactose fermenters. Although the normal habitat of E. coli is the gut of man and 
animals, it may colonise the lower end of the urethra and vagina. Infection with E. 
coli can be spread by contact, ingestion (Faecal-oral-route) and may be associated 
with food. Diseases caused by E. coli include urinary tract infections, diarrhoeal 
diseases, and neonatal meningitis. 
 
1.11.2 Klebsiella spp 
 
The organism Klebsiella was named in honour of Edwin Klebs a 19
th
 century 
German-Swiss microbiologist. Klebsiella spp are Gram-negative rods belonging to the 
family Enterobacteriaceae family. They are facultative anaerobes but growth under 
strict anaerobic condition is poor. The capsule is often pronounced and can be 
produced in greater amount in carbohydrate rich media. Klebsiella spp are non-motile 
but most strains are fimbriated. The normal habitat of this species is the gut of man 
and animals and moist inanimate environments, especially soil and water. Infection 
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may be endogenous or acquired by contact spread. Klebsiella spp are considered to be 
an opportunistic pathogen causing infection in immuno-compromised patients and 
those with underlying health conditions such as alcoholics, those with lung disease, 
diabetics, etc. Klebsiella spp are responsible for 7-10% of hospital associated 
bloodstream infections in Europe, Latin America, and North America (Biedenbach et 
al. 2004). 
1.11.3 Enterobacter  spp 
Enterobacter spp are Gram-negative rod-shaped bacteria that are facultatively 
anaerobic. They are motile and belong to the family Enterobacteriaceae. Enterobacter 
species are found in the natural environment in habitats such as water, sewage, 
vegetables, and soil. The most clinically important are the Ent. Cloacae and Ent. 
aerogenes, which can cause opportunistic infection in immuno-compromised patients. 
Cephalosporins are contra-indication because of the risk of treatment failure due to 
inducible β-lactamases. 
 
1.11.4 Serratia marcescens 
Serratia is a genus of Gram-negative, facultative anaerobic rod shaped bacteria of 
Enterobacteriaceae family. Serratia marcescens is the species, in this genus, most 
often encountered in clinical specimens (Greenwood et al. 1992). Most Serratia are 
motile by means of peritrichous flagella and are facultative anaerobe. They belong to 
Enterobacteriaceae family. Serratia are distributed ubiquitously in soil, freshwater 
and sea water. Serratia marcescens thrives in moist environments and human disease 
caused by this organism are often assocaited with septicaemia, wound and respiratory 
tract infections has been reported (Hejazi and Falkiner 1997). Serratia strains are 
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commonly resistant to cephalosporins and an aminoglycoside is usually the most 
reliable drug of choice. 
1.11.5 Morganella morganii 
Morganella morganii is a Gram-negative rod that is a facultative anaerobe. It is found 
in the faeces and the intestines of humans, dogs, and other mammals. It is known to be 
a causative organism of opportunistic infections in the respiratory tract, the urinary 
tract, and in wound infections. This organism is characteristically resistant to many β-
lactam antibiotics, which may lead to delays in proper treatment (Mugnaioli et al. 
2005). 
1.11.6 Stenotrophomonas maltophilia 
Stenotrophomonas maltophilia is an aerobic, non fermentative Gram-negative 
bacterium and human infection caused by this organism is difficult to treat. They can 
occur almost in any aquatic or humid environment including the drinking water 
supply (Hoefel et al. 2005, Cervia et al. 2008). S. maltophilia is recognized as an 
opportunistic pathogen causing severe infection in immunocompromised patients 
(Safdar and Rolston 2007, Tan et al. 2008). S. maltophilia colonization rates in 
individuals with cystic fibrosis have been increasing (Waters et al. 2007). S. 
maltophilia is naturally resistant to many broad spectrum antibiotics including 
carbapenems due to the production of inducible chromosomal metallo-β-lactamases 






1.12     Aims of this study: 
 
 To determine the susceptibility pattern of Gram-negative blood culture 
isolates. 
 To determine the molecular diversity associated with the dissemination of 
ESBL genes, particularly blaCTX-M-15, in blood culture isolates of E. coli. 
 Comparison of the diversity and ESBLs of Enterobacter cloacae isolated in 
Edinburgh with those isolated in Cairo, (an area that has had a bigger problem 
with resistance). The seldom studied Ent cloacae,carrying the blaCTX-M-14 gene 
was also investigated. 
 Sulphonamide resistance genes are closely associated with blaCTX-M-15 genes. 
The final aim was to study integrons and the persistence of these 
sulphonamide resistance genes in blood culture isolates in a population where 





2 Materials and methods 
 
2.1 Bacterial strains 
 
A total of 100 Gram-negative isolates which had been assumed to be resistance to 
carbapenems were collected from New Royal Infirmary of Edinburgh. The period of 
sample collection were between July 2009 and December 2009. The isolates comprise 
65 E.coli, 11 Enterobacter cloacae, 8 K. pneumoniae, 4 K. oxytoca, 3 Serratia 
marcescens, 2 Morganella morganii, and 1 Enterobacter asburiae, 5 
Stenotrophomonas maltiphilia and 1 Cupriavidus pauculus. All isolates were from 
blood cultures. Also 3 Enterobacter cloacae isolates from Egypt were examined in 
addition. The first was isolated from a male in ICU in March 2010. The second was 
isolated from sputum of a female in ICU in March 2010 and the third from a female 
also in ICU in March 2011. 
2.1.1  Control strains 
 
The control strains used for this study were E.coli NCTC 10418, Staphylococcus 
aureus NCTC 6571, and Pseudomonas aeruginosa NCTC 10662. 
 
2.2 Identification of isolates 
 
Isolates were initially identified in the hospital using standard microbiology 
techniques. The isolates were confirmed by me using API (20E/20NE) methods 
according to manufacturer’s instructions and PCR molecular identification of strains 
by sequencing of approximately 500bp fragment of the 16S rRNA gene using 
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previously described universal primers(Kommedal et al. 2008). Sequences were then 
compared to those in the GenBank database using BLASTN to find species with 
similar sequences.   
2.3 Media broths, agars and normal saline 
 
All the media used in this study were from Oxoid (Basingstoke, UK) and were 
reconstituted with distilled water in the laboratory according to manufacturer’s 
instruction and autoclaved before use to ensure sterility. The normal saline used for 
the study was prepared by dissolving 0.85g NaCl (Sigma ultra USA) in 100ml of 
distilled water followed by autoclaving. 
2.4 Antimicrobial susceptibility testing. 
 
2.4.1 Disc Susceptibility Testing 
 
Initial antimicrobial susceptibilities were determined by the disc diffusion method on 
Iso-sensitest Agar (IST Agar) and the susceptibility breakpoints were estimated as 
recommended by BSAC Methods for Antimicrobial Susceptibility Testing version 10 
(Andrews et al. 2011). The antibiotic discs used were obtained from Oxoid 
(Basingstoke, UK). Briefly an overnight broth culture was diluted 1: 500 in sterile 
0.8% saline; the inoculum was spread over the surface of an agar plate in two 
dimensions. An antibiotics disc was applied to the surface of the agar within 15 




2.4.2 Minimum Inhibitory concentration (MIC) 
 
The MICs of the antibiotics were determined using agar dilution method according to 
the guideline of British Society for Antimicrobial Chemotherapy (BSAC) Working 
Party and the MIC concentrations were between 0.008-256mg/L(Andrews et al. 
2011). Briefly, Iso-sensitest (IST) agar was allowed to cool to 50°c before the 
addition to the antibiotic containing plate, then allowed to set and dried at room 
temperature. An overnight broth culture was diluted 1:500 in sterile 0.8% saline and 
approximately 10
4 
of the organism inoculated using multipoint inoculators (Denley: 
surrey.UK) onto the antibiotic containing media. Inoculated plates were incubated 
overnight at 37°c.The MIC is the lowest antibiotic concentration to inhibit all visible 
growth. 
Table 3 Antimicrobial agents used 
 
Antimicrobial Agent Supplier/ Manufacturer 
Kanamycin Sigma-Aldrich (Dorset,UK) 
Aztreonam Sigma-Aldrich (Dorset,UK) 
Cefepime Sigma-Aldrich (Dorset,UK 
Cefotaxime Sigma-Aldrich (Dorset,UK 
Ceftazidime Sigma-Aldrich (Dorset,UK) 
Gentamicin Sigma-Aldrich (Dorset,UK) 
Ampicilin Sigma-Aldrich (Dorset,UK) 
Piperacilin Sigma-Aldrich (Dorset,UK) 
Streptomycin Sigma-Aldrich (Dorset,UK) 
Spectinomycin Sigma-Aldrich (Dorset,UK 
Co-trimoxazole Sigma-Aldrich (Dorset,UK 
Ciprofloxacin Sigma-Aldrich (Dorset,UK) 
Nalidixic acid Sigma-Aldrich (Dorset,UK 
Imipenem Merck (Nottingham, UK) 
Meropenem Astra Zeneca (London, UK 
Ertapenem Merck (Nottingham, UK) 
Cefoxitin Sigma-Aldrich (Dorset,UK) 
Rifampicin Sigma-Aldrich (Dorset,UK) 
Pottasium Clavulanate Sigma-Aldrich (Dorset,UK) 
Cefoperazone Sigma-Aldrich (Dorset,UK 
Cefuroxime Sigma-Aldrich (Dorset,UK 
A list of the antimicrobials used and their suppliers. 
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2.5 ESBLs detection by double disc synergy test 
 
A plate is inoculated as the disc susceptibility above. Synergy between cefotaxime 
and amoxicillin/clavulanic acid were detected by placing the disc 30mm apart and 
incubated at 37°c overnight. ESBLs production is confirmed when a clear cut 
extension of the cefotaxime inhibition zone towards the disc with clavulanic acid 
which indicates the synergy.  
 
2.6 Polymerase Chain Reaction (PCR) Amplification 
 
2.6.1 Extraction of DNA  
 
DNA was extracted by suspending 1 loopful of culture (from a plate incubated 
overnight) in 50μl sterile distilled water. The mixture was then boiled for 10 minutes 
and centrifuged at 13,000 rpm for 1min using eppendorf micro centrifuge 5415D. The 
supernatant was taken and used as template DNA.  
 
Genomic DNA was extracted using Promega DNA isolation kit according to 
manufacturer’s instructions. 
 
2.6.2 PCR reagents 
 
PCR reagents were provided from (Promega, Southampton, UK). The reagents used 
for PCR were: 0.02μm of each primer, 5x green or colourless buffer, 
Deoxynucleoside triphosphates (dNTP) / PCR nucleotide mix (10 mM each), Go Taq 
DNA Polymerase (5u/μl), and MgCl2 solution (25 mM). 
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2.6.3  PCR reactions 
 
The final volume of the PCR reaction mixture was 50 μl. The reaction mixture had 
1μl dNTPs, 3μl MgCl2, 0.2 μl of Taq DNA polymerase, 5µl green /colourless buffer, 
1μl template DNA, 1μl each primer. Sterile Distilled water (38.8μl) was used as 
diluents for the reaction. 
2.6.4    PCR Primers 
 
The primers used were manufactured by Eurofins MWG Operon and Invitrogen life 
technology. The primers used in this study were either from published papers or 
designed using biotools software 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi). Table 4 lists all the 





Table 4 Primers used in this study 
 
Primers Forward Sequence(5’-3’) Reverse sequence(5’-3’) Reference 
CTX-M TTTGCGATGTGCAGTACCAGTAA CGATATCGTTGGTGGTGCCATA (Edelstein et al. 2003) 
CTX-M-1 AAAAATCACTGCGCCAGTTC AGCTTATTCATCGCCACGTT (Woodford et al. 2006) 
CTX-M-2-F CGACGCTACCCCTGCTATT CCAGCGTCAGATTTTTCAGG (Woodford et al. 2006) 
CTX-M-9-F CAAAGAGAGTGCAACGGATG ATTGGAAAGCGTTCATCACC (Woodford et al. 2006) 
CTX-M-8F TCGCGTTAAGCGGATGATGC AACCCACGATGTGGGTAGC (Woodford et al. 2006) 
CTX-M-25F GCACGATGACATTCGGG AACCCACGATGTGGGTAGC (Woodford et al. 2006) 
CTX-M1A CTTCCAGAATAAGGAATC CCGTTTCCGCTATTACAA (Dutour et al. 2002) 
Isecp1 GCAGGTCTTTTTCTGCTCC TTTCCGCAGCACCGTTTGC (Poirel et al. 2003) 
Is26 GCGGTAAATCGTGGAGTGAT ATTCGGCAAGTTTTTGCTGT (Woodford et al. 2004) 
CTX-M-14 AACACGGATTGACCGTATTG  TTACAGCCCTTCGGCGAT (Bou et al. 2002) 
IS903 CATATGAAATCATCTGCGC CCGTAGCGGGTTGTGTTTTC (Poirel et al. 2003) 
aac(6')-Ib-cr  TTGCGATGCTCTATGAGTGGCTA  CTCGAATGCCTGGCGTGTTT (Park et al. 2006) 
orf-513 CTTTTGCCCTAGCTGCGG CTCACGCCCTGGCAAGGTTT (Lartigue et al. 2004) 
orf-477 GCGCATAGTCATCGGCAG CCTGGGACCTACGTG (Literacka et al. 2009) 
Sul1 CGGCGTGGGCTACCTGAACG GCCGATCGCGTGAAGTTCCG (Kerrn et al. 2002) 
Sul2 GCGCTCAAGGCAGATGGCATT GCGTTTGATACCGGCACCCGT (Kerrn et al. 2002) 
intl1 GCCACTGCGCCGTTACCACC GGCCGAGCAGATCCTGCACG (Kerrn et al. 2002) 
hep58 & 59 TCATGGCTTGTTATGACTGT GTAGGGCTTATTATGCACGC (White et al. 2000) 
Sul3 GAGCAAGATTTTTGGAATCG  CATCTGCAGCTAACCTAGGGCTTT
GGA 






(Kommedal et al. 
2008) 
VIM-1 TTATGGAGCAGCAACGATGT CAAAAGTCCCGCTCCAACGA (Yan et al. 2001) 
Intl2 CS TGGGCTGAGAGAGTGGT TTTTTGTGCTGCCATATCCGTG (Ramírez et al. 2005) 
aadA2 TGTTGGTTACTGTGGCCGTA GATCTCGCCTTTCACAAAGC (Randall et al. 2004) 
F11 CTGATCGTTTAAGGAATTTT CACACCATCCTGCACTTA (Villa et al. 2010) 
F1B TCTGTTTATTCTTTTACTGTCCAC CTCCCGTCGCTTCAGGGCATT (Villa et al. 2010) 
F1C GTGAACTGGCAGATGAGGAAGG TTCTCCTCGTCGCCAAACTAGAT (Villa et al. 2010) 
O25pabBspe TCCAGCAGGTGCTGGATCGT GCGAAATTTTTCGCCGTACTGT (Clermont et al. 2009) 
TspE4C2 GAGTAATGTCGGGGCATTCA CGCGCCAACAAAGTATTACG (Clermont et al. 2000) 
ChuA GACGAACCAACGGTCAGGAT TGCCGCCAGTACCAAAGACA (Clermont et al. 2000) 
YjaA TGAAGTGTCAGGAGACGCTG ATGGAGAATGCGTTCCTCAAC (Clermont et al. 2000) 
trpA GCTACGAATCTCTGTTTGCC GCAACGCGGCCTGGCGGAAG (Clermont et al. 2009) 
Oxa-1 like GGATAAAACCCCCAAAGG AA TGCACCAGTTTTCCCATACA (Karisik et al. 2006) 
TEM ATAAAATTCTTGAAGACGAAA GACAGTTACCAATGCTTAATC (K. Lee et al. 2003) 
IncF1A CCATGCTGGTTCTAGAGAAGGTG GTATATCCTTACTGGCTTCCGCAG (Villa et al. 2010) 
IncF1B TCTGTTTATTCTTTTACTGTCCAC CTCCCGTCGCTTCAGGGCATT (Villa et al. 2010) 
IncF1C GTGAACTGGCAGATGAGGAAGG TTCTCCTCGTCGCCAAACTAGAT (Villa et al. 2010) 
IncF11 CTGATCGTTTAAGGAATTTT CACACCATCCTGCACTTA (Villa et al. 2010) 
IncN GTCTAACGAGCTTACCGAAG GTTTCAACTCTGCCAAGTTC (Carattoli et al. 2005) 
IMP GGAATAGAGTGGCTTAAYTCTC CCAAACYACTASGTTATCT (Ellington et al. 2007) 
SIM TACAAGGGATTCGGCATCG TAATGGCCTGTTCCCATGTG (Ellington et al. 2007) 
SPM AAAATCTGGGTACGCAAACG ACATTATCCGCTGGAACAGG (Ellington et al. 2007) 
GIM TCGACACACCTTGGTCTG AACTTCCAACTTTGCCATGC (Ellington et al. 2007) 
intl2 CACGGATATGCGACAAAAAGGT GTAGCAAACGAGTGACGAAATG (Machado et al. 2005) 
intl 3 AGTGGGTGGCGAATGAGTG TGTTCTTGTATCGGCAGGTG (Machado et al. 2005) 





2.7     Agarose gel electrophoresis of PCR product 
 
 
2.7.1                            10X TAE buffer 
 
The constituents of 10X TAE buffer were: 3.72g of EDTA (Ethylene Diamine Tetra 
acetic Acid) Sodium salt dehydrate 99% (Aldrich produce of USA), 11.4 ml glacial 
acetic acid (Bio keystone Co LLC, California, USA). The final volume of the buffer 
was made up to one litre and the pH was adjusted to 8.0. Just before use, the buffer 
was diluted to1:10 to make 1X TAE buffer. 
 
2.7.2 Visualisation of PCR product 
 
After amplification reaction, the PCR product were analysed in 1.5% agarose gel 
(Fisher Bioreagent) using the following electrophoresis conditions: 100v, 30min on 
1X TAE buffer at room temperature. The molecular weight markers used were 100bp 
and Ikb ladder. After running, the gel was stained with Gel red and then visualise 
under UV Tran illuminator Bio-Rad Gel Doc 2000 (Bio-Rad, Hemel Hemstead, UK) 
 
2.8  Sequencing of PCR product 
 
 
PCR products were purified using QIAquick purification Kit (Qiagen, West 
Sussex.UK) according to the manufacturer’s instructions. Primers were diluted to 3.2 
picamole.1μl of the diluted primer and 5μl of the purified PCR product were sent for 
sequencing .The sequencing was carried out in the Gene pool Genomics facility at the 
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University of Edinburgh (http://genepool.bio.ed.ac.uk/).  The DNA sequence result 
were analysed using BLAST and compared with published sequence on the website 
http//www.blast.ncbi.nlm.nih.gov/genbank. Protein sequences were obtained using 
Expasy translate website (http//www.expasy.ch/tools/dna.html). 
 
2.9     Pulsed-field Gel Electrophoresis (PFGE) 
             
2.9.1                       Agarose plug preparation 
 
PFGE was applied to assess the clonality of the bacteria isolated. Strains were grown 
overnight in 5ml LB broth at 37
o
C and harvested by centrifugation at 3000g for 20 
mins using Sorval RT7 plus centrifuge. The supernatant was removed and the pellet 
suspended in 1ml cell suspension Buffer (100mM Tris-HCL, 100mM EDTA pH 8). 
Each cell suspension was adjusted to cell density between 1.3-1.4 absorbance at 
610nm wavelength using a spectrophotometer. 500μl cell suspensions were incubated 
at 55
o
C for 10mis in a water bath.  Aliquots of 25μl of Proteinase K (20mg/l) were 
added and the suspension mixed gently by inversion. An equal volume of melted 1% 
Seakem Gold agarose: 1%SDS in TE buffer (10mM Tris, ImM EDTA, pH 8) was 
added to the suspension and mixed gently by inverting the tube 12 times. The mixture 
was immediately dispensed into wells of plug mold and allowed to solidify at room 
temperature for 5mins and at 4
o
C for 10mins. The plugs were removed from plug 
mold and transferred to 2ml cell lysis solution-1 (50mM Tris, 50mM EDTA, 
2.5mg/ml lysozyme, 1.5mg/mls Proteinase K pH 8) and placed in a water bath at 37
o
C 
for 1hr. The plugs were transferred into 2ml cell suspension buffer-2 (0.5 EDTA, 1% 
Sarcosyl, and Proteinase K 400μg/ml) and places in a 55
o
C water bath for 2hrs.The 





C for 15mins each and then 3 times in TE buffer( 10mM Tris-HCL,0.1mM 
EDTA pH 7.6) at 55
o
C for 15mins each .After the last wash, TE buffer was added and 
the plug stored at 4
o
C until use. 
 
2.9.2 Agar rose plug digestion 
 
The plugs prepared above were equilibrated in 200μl of the restriction endonuclease 
buffer for 45mins at 37
o
C. The restriction buffer was replaced with another 100μl 
buffer containing 30u of Xbal (PromegaUK) restriction enzyme and 1ul BSA. The 
tubes were incubated in a water bath at 37
o
C for 18hrs. 
 
2.9.3 Gel preparation and running conditions 
 
A 1% pulsed-field certified agarose gel was prepared in 0.5x TBE buffer (0.089M 
Tris base, 0.089M Boric acid.2.5mM EDTA). Plugs were loaded into the wells of the 
PFGE agarose gel. Electrophoresis was performed in a CHEF-DRII system for 22hrs 
at 6.0volt/cm with a pulse time 5-45 seconds at 13
o
C in 0.5x TBE buffer. A lambda 
ladder PFGE maker (New England Biolabs) was used as the size standard. Gels were 
stained in Gel Red for 30 mins and visualised under UV with Bio-Rad GelDoc 
system.  
 
2.9.4 Interpretation of the PFGE 
 
Cluster analysis was performed using Bio Numeric Software version 4 by the 
unweighted pair group method with arithmetic averaging (UPGMA). DNA 
relatedness was calculated by using the band-based Dice co-efficient with a tolerance 
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setting of 1.5% band tolerance and 1.5% optimization setting for the whole profile. 
Isolates which cluster together with a similarity of ≥ 85% were considered to belong 
to the same PFGE type and the results were obtained in a phylogenetic tree. 
 
2.10   Plasmid DNA isolation 
 
Several methods of plasmid extraction were used in this study including Qiagen midi 
and mini kit. Plasmid DNA was also extracted and isolated by a modification of the 
alkaline lysis method of described by Kado and Liu (Kado and Liu 1981). Briefly a 
loopful of bacteria grown on a plate was suspended in 60μl suspending buffer (50mM 
Tris-HCL,1mM EDTA, pH 8) ensuring suspension are uniform. 600μl of lysis buffer 
(50mM Tris base, 3%SDS, pH12.5) were added and mixed briefly. The mixture was 
incubated at 56
o
C for 1hr. Three hundred μl of a mixture of  phenol, chloroform, and 
isoamylalcohol  in the proportion of 25:24:1 was added and mixed well. The mixture 
was centrifuged for 30 mins. The upper aqueous phase containing the plasmid was 
transferred to a fresh tube. 
 
Plasmid DNA was also extracted using the Qiagen Midi prep kit according to 
manufacture’s instructions.  Plasmids were stored at -80
o
C. This was used for the 
transformation assay. 
 
2.10.1 Plasmid Profile by S1 Nuclease digestion 
 
 
S1 is an endonuclease that is more active against DNA than RNA. This procedure 
converts the circular DNA to a linear form to determine the molecular sizes of the 
plasmids. The closed circular super coiled form moves very slowly, the naked plasmid 
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remains trapped in the wells. The protocol was modified from a previously used 
method by Barton et al, 1995 (Barton et al. 1995). The plugs slices were prepared as 
in the PFGE protocol and were equilibrated into 200μl 1x S1 nuclease buffer 
(Promega UK) at 37
o
C for 45mins. The buffer was replaced with 1x S1 nuclease 
buffer containing 10 units of S1 nuclease and incubated for 45mins at 37
o
C. The 
reaction was stopped with 0.5M EDTA (pH8). The gels were run and stained as 
described previously for PFGE. The plasmid sizes were determined by comparison 
with the PFG lambda ladder.  
2.11         Conjugation assay by Broth Method 
 
 
Conjugation assay were performed in broth with E.coli J62-2(Rif 
R
) as the recipient. 
Overnight LB broth culture of the donor and recipient strains were mixed in the ratio 
of 1:10 in LB broth and incubated at 37
o
C overnight. The cells were collected and 
resuspended in 5.6ml of sterile saline .100μl of the cells were dispensed onto plates 
containing rifampicin with the selective antibiotic and spread with the spreader. The 
plates were incubated at 37
o
C overnight and growths of the transconjugants were 
observed. Controls of each strain were inoculated on the same rifampicin/antibiotic 
containing plate and incubated at 37
o
C overnight.  
2.12  Transformation 
 
2.12.1   Preparation of competent cells 
 
An overnight broth culture of E.coli DH5α was inoculated (1:100) into 50mls of fresh 
LB broth in a sterile 250ml flask at 37
o
C on the shaker until approximately 0.5 
absorbance at 600nm wavelength. The culture was placed on ice for 30mins. The cells 
were pelleted by centrifugation at 4
o
C for 10mins. The supernatant was removed and 
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the pellets resuspended in 25mls of sterile ice cold 0.1M CaCl2 and placed on ice for 
30min. The cell suspensions were centrifuged at 4
o
C for 10mins and the supernatant 
removed. The cell pellet was resuspended in 1ml of sterile ice cold 0.1M CaCl2 and 




2.12.2 Transformation via heat shock 
 
The aliquot of the above competent E.coli DH5α cell were thawed on ice. 2μl of 
purified plasmid was added to the cell, mixed and chilled on ice for 30mins. The cells 
were placed in a water bath set at 42
o
C for exactly 1 minute then placed on ice 
immediately for 2min. One ml of fresh LB broth was added to the cells which were 
then transferred into sterile 15ml centrifuge tube and incubated at 37
o
C in a shaker for 
1hr. Cells were then spread on LB agar containing the selective antibiotics and 
incubated overnight at 37
o
C. 
2.13      Assessment of transconjugants and transformants 
  
Transconjugants and transformants were assessed by susceptibility, plasmid extraction 
and S1 nuclease digestion.  
2.14     Gene Expression analysis 
2.14.1  RNA extraction 
 
Bacterial cultures were grown to an optical density of 0.5-0.8 at 600nm wavelength 
and total RNA extracted using Ribopure Bacteria RNA kit according to the 
manufacturer’s instructions. Extracted RNA was treated with DNase 1 for 30 mins at 
37
o





2.14.2 Estimation of RNA concentration 
 
The RNA concentrations were estimated using the Nanodrop 1000 spectrophotometer 
(Thermo scientific, Cramlington, UK). One μl of the extracted RNA sample were read 
by spectrophotometer and 260/280 absorbance reading were noted .The sample that 
fell between 1.8 and 2.1 were deemed suitable to the cDNA synthesis and reverse 
transcription. 
2.14.3 Reverse transcription (RT) PCR  
 
RT PCR was done with 1pg-1μg RNA as template, using Access quick RT PCR 
System (Promega) according to the manufacturer’s instructions. The numbers of 
cycles for each PCR were 30 cycles, except for 16S rRNA gene, which was for 15 
cycles. 
2.14.4 Gel analysis 
 
RT PCR products were analysed using the Bio-Rad Geldoc 2000 software, Quantity 
one. After electrophoresis on agarose gel and staining, Quantity one was used to semi 
quantitatively assess gene expression. The intensity of the PCR product bands were 
measured and normalised to the intensity of the 16S band before being used to 
compare expression levels between strains. The following setting and conditions were 
used: manual band selection, background subtracted, peak intensity readings 





2.15       Inverse PCR 
 
Purification of DNA was performed on overnight culture using DNA purification kit 
(Promega). Restriction reaction were set up with EcoR1 (Promega) according to 
manufacturer’s instruction and incubated for 4hrs at 37
o
C. The enzyme was 
inactivated by heating at 65
o
C for 20 minutes. A ligation reaction was set up using T4 
DNA Ligase (Promega). T4 DNA ligase catalyses the joining of two strands of DNA 
between the 5’-phosphate and the 3’hydroxyl groups adjacent in either the cohesive-
ended or the blunt-ended configuration. This gives rise to circularised DNA. The 
reaction was incubated at room temperature for 16 hours. A PCR reaction was set up 
using the primers designed for inverse PCR (Table 5) under the following conditions: 
94
o
C for 5min, followed by 30 cycles of 94
o
C for 1min, 58
o
C for 1 min, and 72
o
C for 
1 min then final extension of 72
o
C for 5minutes. The PCR products were run on a 
1.5% agarose gel. 
 
Table 5 Primers used for inverse PCR 
 
 

















     
2.16 PCR bases plasmid replicon sequence typing of IncF  
   
Plasmid replicon sequence typing of IncF plasmid was performed according to the 
protocol described by Villa et al (Villa et al. 2010). The genes encoding replicons FII, 
FIA and FIB were sorted by PCR with the primers as listed in the primer table and the 
sequence was carried out in the Gene pool Genomics facility at the University of 
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Edinburgh (http://genepool.bio.ed.ac.uk/). The alleles were assigned by submitting the 
amplicon sequence to the multilocus sequence typing database 
(www.pubmlst.org/Plasmid). The allele number was used to get the FAB formular; F 






















3 Antimicrobial susceptibility pattern of blood culture 
isolates due to Gram-negatives 
3.1 Introduction 
Blood culture is a essential tool in the diagnosis of severe bacterial infections and it is 
the only tool to detect blood stream infection. Usually the blood stream is sterile. 
Blood stream infection (BSI) is a major cause of morbidity and mortality worldwide 
and one of the most common healthcare- associated infections (Mylotte and Tayara 
2000). Microbiological diagnosis and treatment of BSI is dependent on isolating the 
offending pathogen and determining it susceptibility pattern. The result of the 
susceptibility testing will assist in the choice of antimicrobial agent. Studies have 
shown that BSI due to Gram-negative organisms are associated with increased 
mortality when compared with Gram-positives (Diekema et al. 1999). BSI if caused 
by multidrug resistant bacteria results in a reduction in therapeutic options and will 
need immediate attention. Increasing multidrug resistance is a worldwide concern, 
therefore to tackle this resistance problem, appropriate surveillance by monitoring the 
resistance trend and implementing measures are needed. Appropriate treatment of BSI 
will be enhanced by the knowledge of the antibiotic susceptibility profile of the most 
common bacteria encountered locally in such infection. This will increase the 
probability of selecting an effective antimicrobial for empirical treatment. Appropriate 
antimicrobial therapy has been shown to reduce the mortality among patients with 
Gram-negative bacteria when initiated early (Kang et al. 2003, Leibovici et al. 1997, 




Therefore in this study I aim to evaluate the antimicrobial susceptibility pattern of the 
Gram-negative isolates obtained from blood culture with the aim of improving 
management by choice of therapy and surveillance. 
3.2 Results 
The Gram-negative isolates studied were all from blood cultures and consisted of 65 
E. coli, 11 Enterobacter cloacae, 8 K. pneumoniae, 4 K. oxytoca, 3 Serratia 
marcescens, 2 Morganella morganii, as well as 1 Enterobacter asburiae 5 
Stenotrophomonas maltophilia and 1 Cupriavidus pauculus. E. coli was the most 
frequently isolated followed by Klebsiella and Enterobacter spp. The MICs 
determined for all these isolates is in the appendix. There was a high level of 
resistance (78%) to ampicillin (breakpoint ≥8 mg/L) among the Gram-negative 
isolates tested. Overall resistance to cephalosporins was high with 22% resistance to 
cefepime (break point ≥ 2 mg/L)  23% to cefotaxime (breakpoint ≥ 2 mg/L) and 23%  
to ceftazidime (breakpoint ≥ 4 mg/L) meropenem (breakpoint ≥4 mg/L)  and 
imipenem (breakpoint ≥4 mg/L) were the most active antibiotics against these Gram-
negative bacteria. Intrinsic resistance within various bacteria species may produce 
some doubts; therefore the resistance pattern was determined within each species as 
seen in Table 6 which show the activities of the antimicrobial agent chosen against the 
Gram-negative isolates.   
 
Among the E.coli, 44/65 were resistant to ampicillin and 42/65 to piperacillin 
(breakpoint ≥ 16 mg/L). This level of resistance was high and these penicillins were 
the least effective antimicrobials against these pathogens. The aminoglycosides 
(kanamycin, spectinomycin and streptomycin) exhibited a slightly higher level of 
resistance than the cephalosporins tested. The E. coli strains resistance to cefotaxime 
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or ceftazidime were investigated further in this thesis.  The carbapenems: meropenem 
and imipenem, were active against E. coli with no resistance to these drugs from any 
strains of E.coli tested and only 2 (3.1%) E.coli were resistant to Ertapenem (break 
point ≥ 1mg/L). 
 
Among the Klebsiella spp: 8/12 were resistant to ampicillin and 6/12 were resistant to 
piperacillin. It is important to note that it is generally accepted that Klebsiella spp are 
intrinsically resistant to ampicillin due to the production of β-lactamase (Fu et al. 
2007). There was no resistance to the cephalosporins tested. Again there was no 
resistance to the carbapenems tested among the Klebsiella spp. 
 
The Enterobacter spp were found to be resistant to the penicillins (ampicillin 75%, 
piperacillin 83.3%) and most of the antibiotics tested. There were no resistance to the 
carbapenem, imipenem and meropenem although 50% were found to be resistant to 
ertapenem. The Enterobacter spp resistance to cefotaxime and ceftazidime was 
investigated further in this thesis. Enterobacter spp are known to produce inducible 
cepharosporinase. 
 
The M. morganii were susceptible to all the antibiotics tested. The S. marcescens were 
susceptible to all the antibiotics tested except ampicillin. The S. maltophilia were 
resistant to all the antibiotics tested, although it is known to produce an inducible 





Table 6 Antimicrobial susceptibility pattern of the Gram-negative isolates. Figures show number and percentages resistant 
 
Antibiotics E.coli (n=65) 
(%) 
Klebsiella spp (n=12) 
(%) 
Enterobacter spp (n=12) 
(%) 
S. maltiphilia  (n=5) Serratia marcescens (n=3) M .morganii  (n=2) Cupriavidus pauculus (n=1) %resistance 
Ampicillin 44 (67.69) 12 (100) 12 (100) 5 3 1 1 78 
Aztreonam 8 (12.31)  0 8 (66.7) 5 0 0 1 22 
Cefepime 8(12.31) 0 8 (75) 5 0 0 1 22 
Gentamicin 8 (12.31) 0 0  4 0 0 1 13 
Cefotaxime 9 (13.9) 0 8 (66.7) 5 0 0 1 23 
Ceftazidime 9 (13.9) 0 8 (66.7) 5 0 0 1 23 
Ertapenem 2 (3.1) 0 6 (50) 5 0 0 1 14 
Meropenem 0 0 0 5 0 0 1 6 
Imipenem 0 0 0 5 0 0 1 6 
Piperacillin 42 (64.62) 9 (75) 10 (83.3) 5 3 0 1 71 
Kanamycin 21 (32.31) 0 7 (58.3) 5 0 0 1 34 
Co-trimoxazole 32 (49.23) 1 (8.33) 10 (83.3) 5 0 0 0 48 
Spectinomycin 17 (26.2) 1(8.33) 9 (75) 5 0 0 1 33 
Streptomycin 21 (32.31) 1(8.33) 4(33.33) 5 0 0 1 32 




Table 7 MIC50 and MIC90 values for E. coli 
 
 mg/L 
SXT PIP CAZ CTX ATM GEN FEP AMP MER IMP ERT 
MIC50 2 16 0.12 0.12 0.12 0.12 0.12 32 0.03 0.06 0.06 
MIC90 >128 128 16 64 >128 8 32 >128 0.25 0.12 0.12 
 
 
Abbreviations: CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; PIP = piperacillin;  
SXT = co-trimoxazole; GEN = gentamicin; ERT = ertapenem; IMI = imipenem;  
MER = meropenem; ATM=aztreonam; AMP=ampicillin 
 
MIC50 and MIC90 defined as the antimicrobial concentration that inhibits growth of 
50% and 90% respectively of all isolates tested for a particular species of organism. 
The MIC50 and MIC90 were calculated for the E. coli isolates. This was not calculate 
for the other species because the sample sizes were too small. Strains with high MICs 
will have a disproportionately high influence on the MIC50 and MIC90 values. MIC50 
and MIC90 are shown in table 7. 
 
According to the MIC90 the carbapenems (meropenem-0.25; imipenem-0.12 and 




3.3 Discussion  
The presence of bacteria in the blood of a patient has substantial clinical importance. 
The goal of this study is to characterise the antibiotic susceptibility profile of the 
isolated Gram-negative bacteria from blood cultures, which will help in appropriate 
therapy to increase the chance of survival for patients with such infections. The most 
frequently isolated Gram-negative species from this study is E. coli followed by 
Enterobacter spp and Klebsiella spp. E.coli is the leading cause of BSI involving 
Gram-negative bacteria (Weinstein et al. 1997) and multi-drug resistant E. col , 
particularly those with ESBLs, are endemic in many healthcare settings. Multidrug 
resistant organisms are bacteria that are resistant to three or more class of antibiotics. 
With this definition some of these isolates in this study show the characteristics of 
multi drug resistance. Analysis of the antibiogram infers that some isolates were 
ESBL producers, which are marked by resistance to cefotaxime, ceftazidime or 
aztreonam. They were investigated further in this thesis. It has been shown that 
ESBLs producers are often associated with multidrug resistance (Dimude and Amyes 
2013). Most isolates in this study were sensitive to the carbapenems tested except the 
S. maltophilia, Enterobacter spp, two E.coli and Cupriavidus pauculus. The 
resistance in S. maltophilia could be attributed to the production of two chromosomal 
L1 and L2 β-lactamases produced by this species. The resistance the E. coli to 
ertapenem is attributed to efflux mechanism or change in outer membrane 
permeability. These two E. coli isolates were not resistant to imipenem and 
meropenem unlike those isolated in some parts of Europe (Rossolini and Mantengoli 
2008). Resistance to ampicillin and piperacillin was recorded amongst E. coli isolates. 
Some multidrug resistance Enterobacter spp were also seen in this study. The high 
rates of ceftazidime resistance among Enterobacter spp suggests a high prevalence of 
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stably derepressed AmpC cephalosporinase-producing strains (Livermore and 
Woodford 2006), however this was outside the remit of this study. 
 
The susceptibility pattern collected from this study shows that some antibiotics may 
have very limited usefulness in the treatment of BSIs caused by some of these Gram-
negative bacteria; for instance the large numbers of E. coli isolates were found to be 
resistant to ampicillin and piperacillin. E. coli has been found to be frequently 
resistant to penicillins but rarely to this degree (Oteo et al. 2005). The carbapenems, 
imipenem and meropenem, stand out as the most potent agents for treatment of BSIs 
caused by these Gram-negative bacteria; however the use of these drugs will 






4 Molecular diversity associated with the dissemination of 
CTX-M-15 β-lactamase gene in blood culture isolates of 
Eschericia coli from Edinburgh 
4.1 Introduction 
CTX-M extended-spectrum β-lactamases (ESBLs) are now widely distributed in 
multiresistant Enterobacteriaceae worldwide (Bonnet 2004, Nicolas-Chanoine et al. 
2008, Woodford et al. 2004). In E.coli, the ST131 clone is mainly responsible for 
carrying plasmid-encoded CTX-M-15 β-lactamse gene (Coque et al. 2008b, 
Woodford et al. 2009). In England, the CTX-M β-lactamase was first identified in a 
Klebsiella isolate in 2000 (Alobwede et al. 2003), followed by an outbreak in a 
Birmingham Hospital (Brenwald et al. 2003). Since then, the CTX-M-15 
β-lactamases rapidly became the most prominent CTX-M enzyme in England  
(Mushtaq et al. 2003). 
 
Previous studies in our laboratory on Klebsiella spp isolated in Edinburgh showed 
five different clones carrying the blaCTX-M-15 gene (Younes et al. 2011), indicating that 
plasmid transfer was likely to be an important agent of Horizontal Gene Transfer 
(HGT). The PCR-based replicon typing (PBRT) can identify the relationship between 
different plasmids and the epidemiology of HGT (Carattoli et al. 2005). By this 
technique it has been shown that plasmids of the IncF (FIA, FIB, FIC, FII) 
incompatibility family are the most widely disseminated and are commonly found in 
E. coli (Johnson et al. 2007, Marcadé et al. 2009). Furthermore individual E coli 
clones, such as ST131, have co-linkage of the blaCTX-M-15 with other β-lactamase 
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genes such as blaTEM-1, blaOXA-1 and the fluoroquinolone resistance gene aac(6')-Ib-cr 
(Karisik et al. 2006, Coque et al. 2008b, Woodford et al. 2009). 
 
Therefore, to examine the fluidity of the blaCTX-M-15 in a major Scottish teaching 
hospital, I have identified the plasmid incompatibility group, replicon sequence type 
and the total plasmid content of each of the strains carrying the blaCTX-M-15. gene.  I 
assessed the clonal relationship between the isolates and characterised the genetic 
environment of the blaCTX-M-15 gene to determine whether these genes derived from 




4.2.1 Susceptibility profile and characterisation of the 
resistance genes  
Seven E. coli and six E. cloacae strains were positive with double disc and 
combination disc tests, characteristic for the carriage of ESBLs. This is detected by 
clavulanic acid synergy with either cefotaxime and/or ceftazidime as shown in figure 
7. For the purpose of this chapter, only seven E. coli isolates will be discussed. All 
seven E. coli strains were found to be multidrug resistant. These isolates were 
resistant to all antibiotics tested with MIC of ≥128mg/L for ampicillin, piperacillin, 
co-trimoxazole, nalidixic acid and aztreonam. The MICs for the remaining antibiotics 










The clavulanic acid containing disc in the middle is inhibiting the β-lactamase, thus 










CTX CAZ FEP FOX CPZR CXM  CIP  GEN 
35 128 32  32 4 >128 >128  64  8 
58 >128 64  64 8 >128 >128  >128  64 
71 >128 64  64 8 >128 >128  >128  64 
202  64 16 16 16  128  128  >128  8 
270 >128 128  64 8 >128 >128  >128  64 
274 >128 128 >128 8 >128 >128  >128  64 
280 >128 128  128 8 >128 >128  >128  64 
 
Abbreviations: CTX=cefotaxime; CAZ=ceftazidime; FEP=cefepime; FOX=cefoxitin; 
CPZR=cefoperazone; CXM=cefuroxime; CIP=ciprofloxacin; GEN=gentamicin   
The table show the resistance pattern of the E. coli CTX-M-15 containing isolates 
 
 
A multiplex PCR was done to detect the CTX-M groups of the isolates with ESBLs 
characteristics. blaCTX-M genes were detected in all seven of the E. coli isolates and six 
E. cloacae isolates by the multiplex PCR. Figure 8 shows an example gel with results 





Figure 8 Agarose Gel Electrophoresis of a multiplex PCR shows CTX-M group 1 
and 9 bands (L1-Molecular Weight marker 1kb, L2-Molecular weight Marker 
100bp, NC-Negative control, P1-Positive group 1 control =415bp, P9-Positive 
group 9 control =205bp 
The gel show a multiplex PCR for the detection of CTX-M group 1 and 9 
 
For the purpose of this chapter only the six E. coli isolates showing positive for CTX-
M-1 group will be discussed. The whole gene was amplified by PCR and when 
sequenced, all the isolates were confirmed of having blaCTX-M-15 by comparison of the 
sequence in BLAST software of the National Centre for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov). 
 
All the isolates, but one, were found to possess the gene for the OXA-1 β-lactamase 
and fluoroquinolone acetylating enzyme (aac(6’)-Ib) when amplified by PCR. The 
PCR gel showing the 482 product base pair detection of aac(6’)-Ib gene is as shown 




Figure 9 PCR for aac(6')-Ib-cr gene 
 
 
aac(6’)-Ib-cr gene = 482bp 
The band on the PCR gel was measured at 482bp and shows the detection of aac(6’)-
Ib-cr gene in the six E.coli isolates which confers resistance to fluoroquinolones 
 
Upon sequencing, the aac(6’)-Ib variant was found to be aac(6’)-Ib-cr. The cr in 
aac(6’)-Ib-cr means ciprofloxacin (fluoroquinolone) resistance showing that this 
variant can induce resistance against fluoroquinolones.  
 
TEM ESBL sort by PCR was found in five isolates as shown in the representative gel 
in figure 10. The TEM primers amplified a 1080 product base pair. The sequence 





Figure 10 Representative TEM PCR gel                                          TEM = 1080bp 
 
 
The PCR show the detection of TEM-1 ESBL in five of the E.coli isolates. 
 
The summary of the characteristics of each isolate is as summarised in table 9 
showing different resistance genes identified.
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35 + - - - + +    - IS26,IsEcp1  IS26 FIA,N,FII F2:A1:B- - 
58 + + + + - + + ISEcp1 ORF477 FIB,FIA,N,FII F33:A1:B26 + 
71 + + + + - + + ISEcp1 ORF477 FIB,FIA,N,FII F33:A1:B26 + 
202 + - + + + + - IS26,ISEcp1 ORF477 FIA,N,FII F2:A1:B- + 
270 + + + + - + + ISEcp1 ORF477 FIB,FIA,N,FII F33:A1:B26 + 
274 + + + + - + + ISEcp1 ORF477 FIB,FIA,N,FII F33:A1:B26 + 
280 + + + + - + + ISEcp1 ORF477 FIB,FIA,N,FII F33:A1:B26 + 
  
* The replicon sequence types of the IncF plasmid were analysed for genes encoding replicons FIA, FIB, and FII following the protocol at 
http://pubmlst.org/plasmid/ 
The table show the genes identified in each E. coli isolate and the genetic environment of the CTX-M-15 gene. The result of the plasmid replicon 






Conjugative transfers of the resistant determinant (cefotaxime resistance) of 
blaCTX-M-15 into E. coli J62-2 strain were achieved in six out of the seven isolates; the 
final strain would not transfer blaCTX-M-15 despite several attempts (Table 9). 
 
4.2.3 Plasmid Profiling  
Two different methods were used to analyse the plasmid content: plasmid extraction 
followed by S1 nuclease plasmid PFGE and replicon sequence typing. S1 nuclease 
PFGE and plasmid extraction revealed that all the isolates contain detectable plasmid 
DNA. Four of the isolates (58, 71, 274, 280) possessed seven plasmids, one isolate 
(270) had eight plasmids and two isolates (35, 202) had four plasmids. The gel picture 
of the plasmid profile is in the appendix. The plasmid sizes ranged from ~3kb to 
300kb. After the conjugation experiment, two plasmids were transferred from five 
isolates and three plasmids transferred from one isolate (figure 11). 
The transferred plasmids were cut out from the gel, extracted and cleaned. This was 
used as a DNA template to determine which plasmid carried the bla CTX-M-15 gene. 
After performing PCR on all the extracted plasmids, the blaCTX-M-15 was found to be 





Figure 11 Plasmid profile of the transconjugants 
 
The gel show the transfered plasmid with five of the E. coli  having two plasmid and 
one isolate having three plasmid. One of the E. coli isolate could not transfer plasmid. 
 
 
PCR was used for the amplification of the gene encoding replicons IncFIA (product 
462 bp), IncFIB (product 683 bp), IncFII (product 262 bp) and IncN (product 559 bp). 
IncFIC was not detected in any of my isolates. The replicon typing of the isolates 
revealed IncFIA (n=7), IncFIB (n=5), IncFII (n=7) and IncN (n=7) as shown in Table 





Figure 12 PCR of IncFIB up and Inc FII down showing the presence of the 
plasmid replicons. 
M = 100bp ladder; N = Negative control; Inc FIB = 683bp; Inc FII = 262bp 
The PCR show the detection of the Inc FII and Inc FIB in the E. coli isolates 
 
Sequence analysis of the IncF amplicons was done using software on the website -
http://pubmlst.org/plasmid.  Within the IncFII replicon, F2 and F33 alleles were 
identified in two and five isolates respectively. The sequence of the F2 and F33 allele 
were compared on the multialin website (http://multalin.toulouse.inra.fr/multalin/) to 







Figure 13 Sequence analyses of IncFII alleles 




The difference in nucleotide sequence between F2 and F33 can be seen in the 
alignment in figure 13.  
Within the FIA replicon, only the A1 allele was identified in all isolates. Also within 
FIB replicon, only B26 was identified in five isolates. All the sequences of the IncF 
replicon alleles found in this study can be found in the appendix. 
IncF replicon sequence typing was now arranged using the FAB (FII FIA FIB) 
formulae discriminating IncF plasmid variants according to the allele type and 
number identified for each replicon. This shows two types; F2:A1: B- plasmid was 




4.2.4 PFGE, ST131 determination and phylogenetic 
grouping 
 
PFGE showed ≥85% similarity was observed in four isolates (58, 71,274,280), but all 
the others were more diverse, though related, as shown in Figure 14. Isolates 58, 71, 
280, and 270 were found to be in one cluster with ≥92% similarity. Isolates 202, 270, 
and 35 were found to be in a different cluster with ≥90 similarity among them. 
 




The figure show the PFGE dendogram showing the genetic relatedness among the 
CTX-M-15 isolates. 
 
The phylogenetic analysis was determined by a triplex PCR assay using a 
combination of three DNA markers (chuA, yjaA and TspE4C2). The PCR revealed 
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that all the isolates were positive for chuA (279 product bp), yjaA (211 product bp) 





Figure 15 Triplex PCR showing Phylogenetic grouping N=negetive control 
L=1kb ladder 
 
The PCR show the isolates were positive for the DNA markers and were used to 
detect the phylogenetic group. 
 
The decision tree below was used to determine the phylogenetic group of the E.coli 
by using the result of the PCR amplification above. 










From the analysis using the tree in figure 16 above, all the isolates belong to the 
phylogenetic group B2. 
 
PCR with 025pabBspe primers was used to amplify a 347bp fragment of the pabB 






Figure 17 PCR detection of the 025b-ST131 clone 
            N = negative control; M = ladder; pabB =347;  trpA =427 
The PCR gel show the detection of the gene fragment specifically associated wit 
ST131 clone. 
 
The control for this PCR targeted a 427bp fragment of the trpA gene to confirm that 
any amplification failure with the pabB was not due to poor DNA quality or failure of 
the PCR itself. This allele specific PCR discriminating the O25b-ST131 were positive 
for single nucleotide polymorphisms in the pabB gene for all seven isolates.  
 
 
4.2.5 Genetic Environment of blaCTX-M-15 
 
 
PCR amplification and subsequent sequencing identified the Insertion sequence 
ISEcp1 upstream of blaCTX-M-15 in five of the isolates while, in two isolates, ISEcp1 
was truncated with IS26. The diagram in Figure 20 shows the arrangement of the 
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upstream region found in this study. Analysis of the sequence of the two isolates with 
IS26 truncation shows the putative -35 and -10 promoters located within the IS26 with 
the -35 ( t t c a t g ) and -10 ( g g g g a t g a t )  lying 140bp and 115bp respectively 
upstream of the blaCTX-M-15  start codon. The locations of these putative promoters are 












In the other five isolates, the typical promoters regions – 35 TTGAAA and -10 




The PCR amplification of downstream region for orf477 showed a PCR product band 
in isolate 35 higher than the others as seen in figure 19. The sequences were 
subsequently analysed and revealed orf477 in all the isolate but one. 
 
 
Figure 19 PCR amplification gel for downstream blaCTX-M-15. 
 
The PCR gel show the detection of the downstream region of the CTX-M-15 for the 
orf477. The PCR product was sequenced to analyse the gene. 
 
The sequence showed a 47bp intergenic region between the blaCTX-M-15 and orf477 in 
all the isolates but that same one. In isolate 35 the insertion sequence IS26 was found 
downstream of the blaCTX-M-15 as opposed to the orf477 found in the other isolates. 
There is a 10bp intergenic region between the blaCTX-M-15 and IS26  
 
The general impression of the genetic environment upstream and downstream of 
blaCTX-M-15 is as shown in Figure 20.
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Figure 20 Alignment of ISEcp1 and IS26 upstream and orf477/IS26 down stream of blaCTX-M-15 
 
 




PCR-based amplification examination of integron shows an 898bp amplicon in two 
(202, 35) out of the seven isolates for the intI1 integrase gene (Table 9). The PCR gel 
representation of the PCR is as shown in figure 21. The intI1 integrase gene was 
confirmed by sequencing and analysis on BLAST software. 
 
Figure 21 PCR Gel Showing intI1, sul1 and sul2 
 
 
The PCR gel show a PCR for the detection of the intI1(898bp), sul1(433bp)and  
sul2(293bp) of the integron. 
 
None of the isolates showed an amplification product with the intI2 and intI3 primers. 
Also sul1 gene which is part of class 1 integron showed a 433bp product size as seen 
on the PCR gel in figure 21 and was found in all the isolates. The sul2 gene was 
present showing a 293bp amplicon in five of the isolates. Furthermore, none of the 
isolates showed an amplification product with the sul 3 primer. The sul genes were 
confirmed by sequencing and analysis on BLAST software.  
 
The PCR for the detection of the variable region were done using the hep 58 and hep 
59 primers and the amplicon sequenced. Upon examination of the sequence for the 
variable region containing the gene cassette, I found the dfrA17 gene encoding a 
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trimethoprim-resistant dihydrofolate reductase and an aadA5 gene encoding 
aminoglycoside-3-adenyltransferase in all isolates. This was also done using BLAST 
software of NCBI. The four isolated that do not have the intI1 integrase gene was 
found to have this gene cassette which is of interest. The diagrammatic representation 
of the variable region showing the structural organisation of the gene cassette is 
shown in the figure 22. 
 
Figure 22 The structural organisation of the gene cassette. 
 
 
The class 1 integron show the Intl integrase with the associated gene cassette of 






CTX-M β-lactamase penetrated and became prevalent in the United Kingdom 
displacing the SHV and TEM ESBL variants. This study provides data on CTX-M-15 
carrying E. coli in blood culture isolates from Edinburgh. CTX-M-15 was first 
isolated in India (Karim et al. 2001) and emerged in the UK in 2001 (Mushtaq et al. 
2003). All isolates belonged to phylogenetic group B2, often associated with extra-
intestinal infection. CTX-M-15 producing E. coli from clinical isolates are often 
found to belong to phylogenetic group B2 (Machado et al. 2006, Pitout et al. 2005, 
Leflon-Guibout et al. 2004). Analysis of the resistance determinants shows the 
presence of blaCTX-M-15 co-existed with blaTEM, blaOXA-1 and aac(6’)-Ib-cr genes. The 
aac(6’)-Ib-cr  variant is known to induce resistance to fluoroquinolones and can be 
seen in this study,were isolates confer resistance to ciprofloxacin and nalidixic acid. 
Similar associations have been described in isolates from Europe and North America 
(Karisik et al. 2006, Boyd et al. 2004, Machado et al. 2006) but not, until now, in 
Scotland. 
 
My analysis found that all four of these isolates were closely related if not identical 
and that all seven isolates were associated with the 025b-ST131 clone. The 025b-
ST131 clone has been responsible for much of the dispersal of CTX-M-15 across the 
world (Nicolas-Chanoine et al. 2008); however, the strains described in this study 
were not all identical. The aac(6’)-Ib-cr gene variant has been reported to be confined 
in E. coli ST131 and has therefore been linked to CTX-M-15 positive isolates (Coque 
et al. 2008a, Pomba et al. 2009). The ST131 E. coli clone has spread rapidly, 
probably as it may have a fitness advantage because of the group B2 genomic 
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backbone (Johnson et al. 2010) that is closely associated with extraintestinal infection 
in E. coli . The clone appears to combine resistance and virulence, which in E. coli, 
have often been somewhat mutually exclusive (Johnson et al. 2003). 
 
This study shows the individual dissemination of the blaCTX-M-15 within the microcosm 
of a major Scottish Teaching hospital. Four isolates had ≥85% similarity; the 
remaining three isolates 202, 270, and 35 were more closely related to each other than 
to the previous four. The PFGE results show the ST131 clone divides into multiple 
genotypes. Genomic diversification can occur within the ST131 lineage reflecting 
DNA rearrangement, mutation and integration of insertion sequence and other genetic 
elements (Lau et al. 2008a). The PFGE results show that the ST131 clone can be 
further differentiated into diverse genotypic groups. The use of sequence type (ST) to 
identify a clone appears to be questionable because of the variation in the PFGE. 
Therefore the use of PFGE is still needed and looks more dependable in the 
identification of a clone and helps in the study of clonal spread.   
 
blaCTX-M-15 genes in our isolates were found to be associated upstream with an ISEcp1 
and two of our isolates has ISEcp1 truncated with a copy of IS26 (Figure 20). ISEcp1 
may provide high level expression promoter for the blaCTX-M-15  (Poirel et al. 2005) 
and has been shown to mediate the transposition of blaCTX-M  genes from the 
chromosome of Kluyvera ascorbata to plasmids (Lartigue et al. 2006). ISEcp1 
identified upstream of blaCTX-M genes plays a vital role in the expression and 
mobilisation of this gene (Poirel et al. 2003, Eckert et al. 2006, Saladin et al. 2002). 
The truncating of the ISEcp1insertion sequence may inhibit the mobilisation of this 
gene and confine its location to the specific genotype. ISEcp1 is a member of the 
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IS1380 family and was first observed in the plasmid pST01 in E. coli (AJ242809). 
The orf477 was found downstream of the CTX-M-15 gene with one isolate having the 
IS26 element downstream. 
 
Integrons promote the dissemination of antibiotic resistance genes. Since sul1 is 
located on class 1 integron, isolates with sul1 should carry the associated integrase 
gene intI1 but unusually this was not found in my study. An interesting observation 
was the presence of gene cassettes in isolates without intI1. The result correlates with 
the  previous finding of a plasmid with a truncated intI1 gene which could give 
similar results (Klockgether et al. 2004). Similarly, in our study the presence of dfr 
and aadA was the combination most frequently detected (Vinué et al. 2008). 
 
In this investigation, an IncN plasmid was always present with IncFII when 
blaCTX-M-15 was identified. Although IncN plasmids have been shown to carry 
blaCTX-M-15 genes in E. coli, spread of this gene has been assumed to be related to 
IncFII plasmid (Coque et al. 2008b, Boyd et al. 2004, Hopkins et al. 2006, Novais et 
al. 2007). This was also true in our study. The IncFII plasmid carrying blaCTX-M-15 has 
been shown also to carry aac(6’)-Ib-cr gene and blaOXA-1 in studies around the world 
(Hopkins et al. 2006, Lavollay et al. 2006). As in my study, blaCTX-M-15 has been 
found previously on F2:A1:B- plasmid from England (Villa et al. 2010) but to my 
knowledge this is the first report of  F33:A1:B26 plasmid carrying blaCTX-M-15.  
Additionally, as far as I am aware, this is the first report of blaCTX-M-15, blaTEM-1, 
blaOXA-1 and PMQR aac(6’)-Ib-cr genes co-existing in the same E. coli bacterial cell 




It is interesting to note that the upstream environment of blaCTX-M-15 in five isolates 
was identical; four were closely related strains. The fifth isolate 270 had a genotype 
much more similar to isolates 35 and 202, both of which had a different upstream 
region. But these two isolates have a different downstream region, IS26 was found in 








5 Molecular characterization and diversity in Enterobacter 
cloacae from Edinburgh and Egypt carrying blaCTX-M-14 and 
blaVIM-4 β-lactamase genes 
5.1 Introduction 
 
Enterobacter cloacae is an important nosocomial pathogen responsible for various 
infections. Management of these infections is often complicated by these organisms 
being multidrug resistant.  (Fernández et al. 2011). Carbapenems are  therefore 
important therapeutic agents for the treatment of multidrug resistant Ent. cloacae. 
However, the production of both ESBLs (Bell et al. 2003, Canton et al. 2002, Tzelepi 
et al. 2000) and metallo-β-lactamases (MBL)(Yan et al. 2002, Luzzaro et al. 2004, 
Sianou et al. 2012) by Ent. cloacae have been reported in different parts of the world. 
In particular, the production of MBLs by Ent. cloacae render them resistant to 
carbapenems, which are primary treatment options for multidrug resistant strains of 
this bacterium. CTX-M type β-lactamases are one of the most prevalent types of 
ESBLs globally (Pitout and Laupland 2008) while VIM β-lactamases are one of the 
most prevalent MBL types (Nordmann and Poirel 2002, Livermore and Woodford 
2000). The genes encoding these ESBLs and carbapenemase are often located on 
plasmids, which play a role in the mobilisation of genetic material by there ability to 
capture and spread these resistance genes (Ktari et al. 2006, Miro et al. 2010). The 
dissemination of these resistance genes can also be attributed to clonal expansion of a 
bacterial host of Enterobacteriaceae.(Woodford et al. 2011) 
 
The  blaCTX-M-14 gene was initially identified in clinical isolates from South Korea in 
1995 (Pai et al. 2001). Since then the  blaCTX-M-14 gene has disseminated globally with 
the report of dissemination via plasmids (Valverde et al. 2009). There has been report 
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in the United Kingdom of Enterobacteriaceae such as E. coli with the blaCTX-M-14 
gene (Livermore et al. 2007) but there is less information on Ent. cloacae possessing 
blaCTX-M-14 genes with only reports from China and Egypt (Khalaf et al. 2009, Liu et 
al. 2009).  
This study compares the Enterobacter cloacae isolates from Edinburgh and Egypt to 
identify the degree of their relatedness or diversity and to characterise the genetic 
environment of the ESBL gene, the molecular mechanism of carbapenem resistance 
and their potential carriage on plasmids- to indicate their mode of spread.  
5.2 Results 
 
5.2.1 Susceptibility testing 
 
 
The Ent. cloacae isolates from Egypt (n = 3) and six isolates that were positive for 
CTX-M-9 group from the multiplex PCR in section 4 figure 8 were examined further 
in this section. The MIC were done using the BSAC method and all isolates were 
found to be resistant to ampicillin, piperacillin, co-trimoxazole, nalidixic acid, and 
aztreonam (MIC ≥128 mg/L). The MICs of the remaining antibiotics tested are shown 




Table 10 MIC of antibiotics for the Enterobacter cloacae clinical isolate 





CTX CAZ  FEP FOX  CIP GEN ERT IMI MER 
3 >128 8 4 >128 2 0.5 2 0.25 0.25 
18 >128 8 4 >128 4 0.5 4 0.12 0.12 
69 >128 4 4 >128 4 0.5 4 2 0.25 
156 >128 4 4 >128 4 0.25 2 0.06 0.25 
157 128 4 4 128 4 2 2 0.06 0.12 
167 >128 16 4 >128 4 0.5 2 0.12 0.12 
E1720 >128 64 8 >128 8 8 64 >128 64 
E4293 >128 64 8 >128 8 8 32 >128 64 
E4303 >128 32 8 >128 8 4 8 2 8 
 
Abbreviations: CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; FOX = cefoxitin;  
CIP = ciprofloxacin; GEN = gentamicin; ERT = ertapenem; IMI = imipenem;  
MER = meropenem 
The table show the E. cloacae CTX-M-14 isolate showing resistance to the antibiotics 
with some isolates showing high resistance to carbapenems tested.   
5.2.2 Efflux Pump activity 
 
The MIC of Ertapenem was done with the addition of 10mg/L of the efflux pump 
inhibitor carbonyl cyanidem-chlorophenylhydrazone (CCCP). 
Table 11 MIC with ertapenem (ERT) +10mg/L CCCP 
 
Isolate No ERT ERT + CCCP 
3 2 0.25 
18 4 1 
69 4 1 
156 2 0.5 
157 2 0.5 
167 2 0.25 
E1720 64 8 
E4293 32 8 
E4303 8 1 
 
The table show the reduction in the MIC of ertapenem in the presence of the efflux 




There was a greater than or equal to two fold concentration decrease in MIC 
concentration for ertapenem in combination with 10mg/L of the efflux pump inhibitor 
CCCP. This indicates that an active efflux pump contributes to ertapenem resistance 
in these Ent. cloacae isolates 
5.2.3 Amplification, sequencing of resistant determinant and 
genetic environment 
 
The PCR amplification of the CTX-M-9 group isolates showed a 905bp amplicon size 
which was sequenced and analysed on the BLAST software of NCBI. A 
representative PCR gel is as shown in figure 23. 
 
Figure 23 PCR gel for CTX-M-14 
 
M = 1kb ladder; N = negative control; blaCTX-M-14 = 905bp 
 
 The PCR gel show the detecton of the CTX-M-14 gene in the Ent. cloacae isolates 
and which were confirmed by sequencing.  
The sequencing results confirmed the presence of blaCTX-M-14 in all Ent. cloacae 
strains tested from Edinburgh and Egypt when analysed by BLAST software of the 




Figure 24 Nucleotide sequence of my Isolate aligned with CTX-M-14 
       A = Adenine T=Thymine   G = Guanine   C = Cytosine 




The sequence was compared with a CTX-M-14 sequence from Genbank and there 
was a change from the original in the nucleotide sequence at positions 372 G→A, 570 
A→G, and 702 A→G as shown in figure 24. However when the sequence was 
translated to amino acids, there was no change in the sequence. The amino acid 




Figure 25 Amino acid translated sequence of isolates aligned with CTX-M-14 
The figure show the conversion to amino acid with no change in the sequence when 




The upstream regions of blaCTX-M-14 were sorted by PCR. A PCR product amplicon 
greater than 1500bp was obtained in two isolates as shown in Figure 26. This was 
sequenced and analysed on BLAST software.    
 
Figure 26 PCR gel for upstream region of blaCTX-M-14   
The PCR gel show the detection of ISecp1 upstream of the CTX-M-14 gene, which 
was confirmed by sequencing.  
 
Analysis of the upstream region by PCR amplification shows, two of the isolates were 
found to possess the insertion sequence ISEcp1 upstream of the blaCTX-M-14 while the 
remaining seven did not have this insertion element. A 43bp intergenic region was 
observed between the insertion sequence ISEcp1and blaCTX-M-14 gene. 
 
A PCR was performed for the detection of carbapenemase by multiplex PCR which 
shows the presence of VIM. Primers to detect the whole VIM gene were used to 
perform a PCR. A 920bp amplicon product size was detected in two isolates and the 
representative PCR gel is shown in figure 27. The amplicon was sequenced followed 
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by analysis on the BLAST software of NCBI. Two of the isolates were found to 
possess the blaVIM-4 metallo β-lactamase gene. 
 
Figure 27 Representative PCR gel for detection of VIM-4 
M = low range plus DNA ladder 
The PCR gel electrophoresis show the detection of VIM-4 in the isolates from Egypt 
and which was sequenced to confirm the gene identity. 
 
A PCR was also used for the detection of different types of integron genes. All the 





Figure 28 Representative PCR gel for class 1 integron 
 
The PCR gel show the detection of Intl 1 integrase among the E. cloacae isolates and 
which was sequenced to confirm the gene. 
 
The representative PCR gel to show the int11 integrase is shown in figure 28. IntI2 
and IntI3, encoded in class 2 and 3 integrons respectively, were not found in any of 
the isolates. PCR with primers Hep 58 and 59 were used to detect the variable region, 
and the amplicon was sequenced and analysed using the BLAST software of the 
NCBI. Upon analysis of the gene cassette of the class 1 integron, the first cassette for 
six of the isolates contained dfrA17, which confers resistance to trimethoprim. The 
second cassette was aadA2, which confers resistance to the aminoglycosides.  
 
In the remaining three isolates, one had no gene cassette while the remaining two 
isolates had blaVIM-4 gene as part of a gene cassette in class 1 integron. The PCR gel 
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showing the combination primers used to detect and identify the arrangement of the 
cassette is as shown in figure 29   
 
Figure 29 PCR gel for the detection of gene cassette. 
The PCR gel shows the detection of the gene cassette and to know the arrangement of 
these genes in the cassette. 
 
Figure 29A shows the PCR with aadA2 forward primer and sul1 reverse primer with 
PCR amplicon approximately 2000bp. Figure 29B shows a PCR with the VIM 
forward primer and aadA2 reverse primer with amplicon size approximately 1400bp. 
The cassette structure shows blaVIM-4 was located downstream of the attl1 
recombination site, followed by the aacA7 cassette, dhfrA1 cassette, aadA2 cassette 





Figure 30 Structural organisations of gene cassettes in Ent. cloacae 
 
The diagram show how the resistance genes are arranged within the integron structure 
with the isolated exhibiting different arrangement. 
 
A PCR was also used to sort the 3’-CS end of the class 1 integron structure. A sul1 
forward primer and orf513 reverse primer was used to get a PCR amplicon of 
approximately 1500bp shown in figure 31. This amplicon was sequenced and 




Figure 31 PCR gel for amplification of 3'CS 
Ladder = 1kb 
The PCR gel electrophoresis show the 3'-CS of the class 1 integron in the E. cloacae 
isolates 
 
Interestingly the 3’-CS of the class 1 integron in the six isolates contained the 
qacEΔ1, sul1 genes and the complex ISCRI insertion element (previously called 
orf513). 
5.2.4 Plasmid Profiling and Analysis: 
 
 
Plasmid analysis revealed that all isolates contained detectable plasmids (Figure in the 
appendix C). Six of the isolates possess four plasmids, two isolates possessed one 
plasmid and one isolate did not contain any detectable plasmids, despite several 
attempts to detect them. The plasmid sizes ranged from ~10kb to 300kb. Analysis of 
the extracted plasmids for the location of the genes revealed blaCTX-M-14 and blaVIM-4 
integron structure on the ~300kb plasmid in two of the isolates from Egypt. The other 
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remaining isolates from Edinburgh did not show the blaCTX-M-14 or the integron 
structure in any of the plasmids. 
 
5.2.5 Conjugation and Transformation Experiment: 
 
 
The plasmids in the six Edinburgh isolates could not be transferred or transformed 
despite several attempts. Conjugative transfers of blaCTX-M-14 and blaVIM-4 into the E. 
coli J62-2 strain were achieved in two of the Egyptian isolates, which showed the 
transfer of a 300kb plasmid. Transformations of the same two plasmids were also 
achieved. The plasmid DNA was extracted from the gel and used as a DNA template 
for PCR. Analysis of the transconjugant and transformant extracted plasmid DNA 
showed that the blaCTX-M-14 and blaVIM-4 genes in the two isolates were located on the 
same 300kb plasmid (Figure 32). The blaCTX-M-14 in the other six isolates could not be 




Figure 32 Plasmid profile of the E1720 and E4293 transconjugants 
 
 
The gel show the plasmid profile of the isolates from Egypt with VIM-4 having 
similar plasmid profile where M is the Marker 
5.2.6 Genetic relationship between isolates by PFGE analysis: 
 
 
PFGE banding patterns were obtained for all the isolates, ≥85% similarities were 
observed for the six Edinburgh isolates. Also two of the Egyptian isolates were found 
to have ≥85% similarity while the remaining isolate did not have similarity with the 









PFGE show the genetic finger printing of the Ent. cloacea isolates with the isolate 
from Egypt and Edinburgh. With the Edinburgh isolates showing ≥90% similarity. 
5.3 Analysis of gene expression 
 
Analysis of the CTX-M-14 and VIM-4 β-lactamase genes showed substantial 
expression of blaCTX-M-14 and blaVIM-4 in some isolates. The PCR products were 
quantified using the Bio-Rad Quantity One Software 4.6.1 (Bio-Rad). Normalization 
of DNA was done with the 16S-rRNA primers with the appropriate amounts of 
serially diluted RNA used for c-DNA synthesis. The results of the expression are 
shown in Table 12. 
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Table 12 Quantification of gene expression (Arbitrary units) 
 
 
Isolate Expression of 16s rRNA gene Expression of blaCTX-M-14 Expression of blaVIM-4 
3 252 189 - 
18 249 108 - 
69 255 152 - 
156 255 255 - 
157 251 255 - 
167 255 255 - 
E4303 255 212 200 
E4293 255 255 212 
E1720 255 255 - 
- indicates no expression detected.  
The table shows that the CTX-M-14 are expressed and the VIM-4 is expressed in two 




I screened the Ent. cloacae isolates collected from Edinburgh and Egypt for their 
antibiotic resistance phenotype. The Edinburgh and Egyptian isolates differed in their 
susceptibility to gentamicin and the carbapenems tested. The Edinburgh isolates were 
susceptible to gentamicin, while the Egyptian isolates were resistant to this antibiotic. 
There also were increased MIC values of imipenem and meropenem in the Egyptian 
isolates compared to the MIC values in the Edinburgh isolates (Table 10). This can 
probably be attributed to the relative degree of regulation and restriction in the use of 




All isolates had MICs ≥128 mg/L to cefotaxime, which can be explained by the 
presence of the blaCTX-M-14 found in all isolates irrespective of the source. This 
β-lactamase (blaCTX-M-14) in Ent. cloacae has not been described previously in the 
Scotland or the UK but has been described only in Egypt (Khalaf et al. 2009) and in 
China (Liu et al. 2009). Analysis of the upstream region of blaCTX-M-14 revealed, in 
isolates E1720 and E4293 from Egypt, the presence of the ISEcp1 insertion sequence 
42bp upstream of blaCTX-M-14. This insertion element contained a -10 and -35 putative 
promoter region able to control the expression of  blaCTX-M-14 (Poirel et al. 2003). The 
ISEcp1 insertion element found upstream of the blaCTX-M-14 gene in the Egyptian 
isolates suggests it may be involved in the mobilisation of the gene. It is important to 
note the time of isolation of these two isolates was ten months apart. None of the 
isolates from Edinburgh possessed this insertion sequence upstream of blaCTX-M-14 
again emphasizing the differences in Ent. cloacae from the two regions.  
 
Carbapenem resistance in Gram-negative bacteria is increasing globally. The high 
MIC of carbapenems tested in isolates E1720 and E4293, from Egypt, could be 
explained by the presence of the metallo-β-lactamase (MBL) gene, blaVIM-4. This is 
the first time that blaVIM-4 and blaCTX-M-14 genes have been described together in Ent. 
cloacae although VIM-1/ CTX-M-15 and VIM-1/ CTX-M-2 β-lactamases have been 
described in the same strains of Klebsiella pneumoniae isolated in Turkey and Spain 
respectively (Yildirim et al. 2007, Cendejas et al. 2010). The VIM-4 MBLs are 
normally found as part of a gene cassette in the integron structure (Nordmann and 
Poirel 2002) and we report a novel arrangement in the integron structure where the 
aadA2 replaced the usual aadA1 and the association with complex ISCR1 insertion 
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element (Figure 30). The difference between the two types of integron structure 
identified in Figure 30 is that the first has insertion of the blaVIM-4 and aadA7 cassette 
upstream of the dfrA genes. Another difference is the presence of the dfrA1 gene in 
the first cassette and the related, but not identical, dfrA16 gene in the second cassette. 
It is important to note that the first integron type is located in the plasmid while the 
second type is not on a plasmid. The Edinburgh isolates do not have the blaVIM-4 in the 
integron structure, in contrast to the Egyptian isolates, confirming the low 
carbapenem MICs found in isolates from Edinburgh. 
 
Interestingly the 300kb plasmids (Figure 32) were found to have both the blaVIM-4 and 
blaCTX-M-14 in the Egyptian isolates. This is the first report of the co-existence of these 
two genes in an Ent cloacae clinical isolate and on the same plasmid in any strain. 
This is a conjugative plasmid and can transfer to other bacteria facilitating the spread 
of these resistance genes. The plasmids from the Edinburgh isolates were neither 
transformable nor transferable in my hands and the analysis of the plasmid showed 
blaCTX-M-14 and its integron structure indicated that it is not located in any of its 
plasmid. Therefore presumably it is in the chromosome. 
 
Identical PFGE patterns were found for the blaVIM-4 /blaCTX-M-14 producing Ent 
cloacae. The Edinburgh isolates were found to be related by PFGE with greater than 
85% similarity. Contact transmission is a possible mechanism of acquisition of these 
stains in these patients with blaCTX-M-14 producing Ent. cloacae in Edinburgh. 
However three isolates from Egypt show 100% relatedness in two isolates with 80% 
relatedness in the third. The three isolates from Egypt were isolated from the same 
ICU with the two identical isolates collected 10 months apart. There was no 
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significant genotypic similarity between the Edinburgh and Egyptian isolates as seen 
in Figure 33. 
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6 Integrons and the persistence of sulphonamide 
resistance genes in blood culture isolates, despite the 




Antibiotic resistance in bacteria depends on the resistance genes that are encoded in 
the bacteria. The quantity of antibiotics used and how they are used contributes to the 
development of resistance. There is an expectation that reduction in the antibiotic use 
and the consequent decrease in selective pressure will promote loss of the resistance 
determinant (Murray 1994). There have been reported successes in decreasing 
antibiotic resistance following implementation of antibiotics reduction policies in the 
UK (Barber et al. 1960, Ridley et al. 1970); for instance a withdrawal in the use of 
prophylactic and therapeutic antibiotics was followed by a reduction in drug resistant 
Klebsiella aerogenes in Glasgow (Price and Sleigh 1970). Furthermore, there are also 
reported successes of these policies world wide: USA (White et al. 1997), Japan 
(Fujita et al. 1994), Finland (Seppala et al. 1997), Germany (Klare et al. 1999), and 
the Netherlands (van den Bogaard et al. 2000). 
 
Sulphonamides target the enzyme dihydropteroate synthase in the folic acid pathway 
in bacteria. There has been a decline in the use of sulphonamides in the UK. 
Sulphonamides were used alone until 1969 when sulphamethoxazole in combination 
with trimethoprim, as co-trimoxazole, was introduced and became widely used in 
clinical practice. Its use was restricted in 1995 because of  the hypersensitivity 
reactions attributed to sulphamethoxazole (Enne et al. 2001). Consequently this study 
is designed to elusidate whether sulphonamide resistance genes still persist, in the 
absence of the use of this drug, in Gram-negative isolates from blood culture in 
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Edinburgh. In particular, the strength of association between sul genes and resistance 
to other antimicrobials were determined and the association of the resistance genes 
with integrons that play a key role in multiple antibiotics resistances. 
6.2 Results 
 
6.2.1 Prevalence of antimicrobial resistance 
 
The MIC of all these isolates is as described previously and in the appendix. Under 
half of the Gram-negative isolates were sulphonamide resistant at break point 
≥4mg/L.  The resistance to other antimicrobials among isolates with sulphonamide 
resistance genes were analysed for strength of association and was demonstrated by 
an odds ratio shown in table 13. This statistical analysis  was performed using 
Medcalc for windows, version 12.4.0 (Medcalc software,Ostend,Belgium) 
 
 
Table 13 Relationship between sulphonamide resistance sul gene and resistance to antibiotics 
 
 
Antimicrobials sul gene present 
(n=45) 
sul gene absent 
(n=55) 
odd ratio(95% confidence 
interval) 
Kanamycin 31 (68.9%) 3 (5.5%) 38.38(10.21 to 144.24) 
Spectinomycin 30 (66.7%) 3(5.5%) 34.67(9.27 to 129.58) 
Piperacillin 44 (97.8%) 27(49.1%) 45.63(5.87 to 355) 
Streptomycin 29(64.4%) 3(5.5%) 30.21(8.11 to 112.55) 
Ceftazidime 18(40%) 5(9.1%) 6.46(2.17 to 19.20) 
Cefotaxime 19(42.2%) 4(7.3%) 9.32(2.87 to 30.24) 
Aztreonam 18(40%) 4(7.3%) 8.20(2.53 to 26.61) 
Gentamicin 11(24.4%) 2(3.6%) 8.74(1.82 to 41.84) 
Cefepime 18(40%) 4(7.3%) 8.68(2.68 to 28.12) 
Ampicillin 41(91.1%) 37(67.3%) 4.99(1.55 to 16.08) 
 
The table show there is a relationship between the presence of sul gene and the 




Specifically, resistances to all these antibiotics in table 13 were significantly (P ≤ 
0.01) associated with sulphonamide resistance (sul) genes 
 
6.2.2 Association of Sulphonamide resistance with other 
resistance determinants  
 
 Sulphonamide resistance genes were detected in 45 out of the 100 Gram-negative 
isolates tested. PCR for detection of sul1 show amplicon product size 822bp while 
sul2 showed 293bp amplicon. The representative PCR gel is as shown in figure 34 
and 33 for sul1and sul2 respectively. 
 
 
Figure 34 A representative PCR gel identifying the sul1 gene 
The PCR gel show the detection of sul1 gene in the isolates with 822bp PCR product 




Figure 35 A representative PCR gel showing the sul2 gene 
M = 1kb ladder 
The PCR gel show the detection of sul2 gene in the isolates with a 293bp PCR 
product sequenced to confirm the gene 
The PCR amplicon were sequenced and the sequence analysed using the BLAST 
software of NCBI.  sul1 genes were detected in 26 strains, 27 strains had sul2 gene 
and none of the isolates was found to have sul3 gene. Eight of the isolates had both 
the sul1 and sul2 genes.  
 
With a PCR followed by sequencing of the PCR product for integrase genes encoded 
in an integron were detected in 26 of the 100 isolates. Intl1 integrase genes were 
detected in 25 strains, intl2 gene in 3 and 2 of the isolates had intl3 integrase gene. 
Two of the isolates had both intl2 and intl1 while one isolate had intl1 and IntI3.  
 
The variable zones were sorted by PCR and sequenced followed by analysis of the 
sequence on the BLAST software. Of the 25 intl1 positive isolates, 20 harboured gene 
cassettes in the variable region (Table 14). Five different gene cassette arrangements 
were identified in the 20 isolates as follows, with the number of isolates shown in 
parentheses: dfrA17 + aadA5 (10), dfrA16 + aadA2 (6), dfrA15 + aadA1 (1), aadA1 
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(2) and bla OXA-1 + aadA1 (1). The structural organisation of the arrangement in the 
variable zone is as shown in figure 36. 
 
Table 14 Types of integron detected and the gene cassette in isolates from blood culture 
 
 
Class of integrase Cassette array Number of isolates 
intI1 dfrA17-aadA5 10 
intI1 dfrA16-aadA2 6 
intI1 dfrA15-aadA1 1 
intI1 aadA1 2 
intI1 oxa-1-aadA1 1 
intI1 - 5 
intI2 dfrA1-sat1-aadA1 2 
intI2 - 1 
intI3 - 2 
 
The table show the class of integron detected with the associated gene cassette and the 





Figure 36 Structural organisation of the variable zone in class 1 integron 
showing gene cassettes. 
The figure show the diagramatic arrangement of the class 1 integron with the gene 
cassette arrangement.  
 
 
Two of the three intl2 positive isolates presented the dfrA1+ sat1 + aadA1 gene 
cassette arrangement (Table 14) and tnsE while no gene cassette was detected in the 
remaining isolate. The diagrammatic representation of the variable region of the class 






Figure 37 Structural organisation of the class 2 integron variable region 
The figure show the class 2 integron with the gene cassette showing the resistance 
gene. 
6.3 Discussion  
 
There is still a high prevalence of sulphonamide resistance genes in our hospital 
isolates despite the reduction in the use of the antibacterial. Although there have been 
reported cases of successful decreases in antibiotic resistance after reduction or 
removal of the antibiotic (Klare et al. 1999, van den Bogaard et al. 2000, Seppala et 
al. 1997), the reason for this is still not totally clear because the studies did not 
consider other factors that may contribute to the decrease, such as the infection 
control measures. In this study there is a significant relationship between isolates with 
sulphonamide resistance genes and resistance with other antibiotics tested (P≤0.01); 
in other words isolates with sulphonamide resistance genes are usually resistant to 
other antibiotics (Table13). 
 
Certain factors can influence the persistence of resistance in the event of antibiotics 
withdrawal, one explanation is the contamination from food which has been reported 
previously (Corpet 1988). Another explanation is the co-selection process were 
multiple resistance gene are found in the same plasmid, transposon or any mobile 
120 
 
element and therefore the use of any antibiotics will select the resistance of all the 
others. This is the case in this study where the sul1 resistance gene is an integral part 
of a class one integron. Integrons are mobile genetic elements capable of collecting 
several resistance genes in the form of gene cassettes and dissemination of these 
genes among strains. Integrons play a key role in multiple antibiotic resistances 
posing potential health risk to the general public. Class 1 integrons were the most 
frequent type of integron detected in our study. Most of the genes found within the 
gene cassette of class I integron in our study correspond to blaOXA-1, dfrA and aadA 
genes conferring resistance to β-lactam, trimethoprim and aminoglycosides 
respectively. The dfrA17 + aadA5 combination was the most frequent gene cassette 
arrangement found in our study. The 3’CS of the class one integron just before the 
sul1 gene contained the qacEΔ1 that confers resistance to the quaternary ammonium 
compounds that are used as antiseptics and disinfectants. In this study most of the 
isolates with sul1 had intI1 but it is interesting to note that three isolates were negative 
for sul1 but positive for sul2 and intI1 and a gene cassette was not detected in these 
isolates. 
 
The class two integron gene cassettes had the dfrA1+ sat1 + aadA1 combination, 
which is a common cassette often found in the variable zone (Kadlec and Schwarz 
2008, Vinué et al. 2008). The sat gene, which encodes a streptothricin 
acetyltransferases, confers resistance to streptothricin. The transposition protein tnsE 
gene was also found in the class 2 integron structure. This arrangement of the class 2 




The sul2 gene is often associated with the resistance gene strAB, which is a  
streptomycin phosphotransferase enzyme conferring resistance to streptomycin (Enne 
et al. 2004). Although the sul2 genes association with strAB  is not regarded as mobile 
genetic element, it has been known to be associated with insertion elements such as 
ISCR2 and IS26 (Toleman et al. 2006, Parkhill et al. 2001). The data in this study 
shows the sul genes were often associated with a mobile genetic element and when an 
antimicrobial resistance is associated with a mobile genetic element, it may be 






7 Summary and Conclusion 
 There was an unusually high resistance to penicillins in Escherichia coli.. 
There were nine isolates of E. coli resistant to cefotaxime. Additionally, all 12 
Enterobacter cloacae isolates were resistant to penicillins and eight were 
resistant to cefotaxime. 
 Most of the cefotaxime resistance was cause by the carriage and expression of 
the blaCTX-M-15 gene. 
 The blaCTX-M-15 gene was predominantly carried on IncF plasmids and its 
spread was largely associated with the transfer of these plasmids from one 
isolate to another. 
 Most E. coli isolates containing the blaCTX-M-15 gene were from related but not 
identical variants of the ST131 clone. 
 There was an absence of the intI1 integrase but this did not appear to exclude 
the presence of the gene cassette which was found in most of the blaCTX-M-15 
gene-containing isolates. 
 This is the first report of blaCTX-M-15, blaTEM-1, blaOXA-1 and PMQR aac(6’)-Ib-
cr genes co-existing in the same E. coli bacterial cell in the United Kingdom.  
 This is the first report of F33:A1:B26 plasmid carrying blaCTX-M-15. 
 This is also the first report of blaCTX-M-14 in Ent. cloacae in the UK. 
 This is the first report of blaCTX-M-14 and blaVIM-4 gene in complex with an 
ISCR1 element to be identified in a Ent. cloacae clinical isolate anywhere in 
the World. The results suggest that there is microevolution of these strains in 
Egypt.  
 This study further provides evidence that the huge reduction in the use of 
sulfonamides has not eliminated the presence of the sul gene. Rather the 
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association of this gene within an integron, which contains other genes that 
confer resistance to antibiotics currently used, contributes to the maintenance 
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Appendix B  
Antimicrobial susceptibility of all the isolates in this study (MIC mg/L)  
                                               Break point (Mg/L) zone diameter (mm) 
 4 16 4 2 2 4 2 8 4 4 1 12 13 16 
          Isolates SXT PIP CAZ CTX ATM GEN FEP AMP MER IMP ERT STREP SPEC KAN 
E.clo 3 >128 128 8 >128 4 0.5 4 >128 0.25 0.015 2 11 0 15 
E.clo 18 >128 128 8 >128 64 0.5 4 >128 0.12 0.25 4 14 0 14 
E.clo 69 >128 64 4 >128 4 0.5 4 >128 0.25 0.03 4 13 0 13 
E.clo 156 >128 128 4 >128 >128 0.25 8 >128 0.25 0.06 2 14 0 13 
E.clo 157 >128 64 4 >128 >128 2 4 >128 0.12 0.12 2 13 0 15 
E.clo 167 >128 64 16 >128 >128 0.5 4 >128 0.12 0.06 2 14 0 15 
E.coli 35 >128 128 32 128 >128 8 32 >128 0.03 0.03 0.015 13 15 16 
E.coli 58 >128 128 64 >128 >128 64 64 >128 0.03 0.06 2 8 13 12 
E.coli 71 >128 128 64 >128 >128 64 64 >128 0.03 0.03 1 0 0 11 
E.coli 202 >128 64 16 64 >128 8 16 >128 <0.008 0.015 0.06 16 12 17 
E.coli 270 >128 128 128 >128 >128 64 64 >128 0.03 0.06 0.015 8 13 12 
E.coli 274 >128 >128 128 >128 >128 64 >128 >128 0.015 <0.008 0.12 8 12 12 
E.coli 280 >128 >128 128 >128 >128 64 128 >128 0.015 0.12 0.03 8 13 12 
E.coli 7 64 4 0.12 0.25 0.25 0.5 0.25  4 <0.008 0.03 0.12 10 16 14 
E.coli 6 16 8 0.5 0.5 0.5 0.03 8  16 0.03 0.06 0.015 10 18 16 
Cup.Var 204 2 128 32 4 16 16 4 >128 4 8 64 8 12 10 
E.coli 116 8 128 0.25 0.12 0.12 0.015 0.25 >128 0.06 0.03 0.12 17 16 15 
E.coli 265 4 128 0.03 0.06 0.12 0.06 0.015 >128 <0.008 0.015 0.03 10 18 17 
E.coli 189 128 128 0.060 0.015 0.12 0.12 0.12 >128 0.015 0.06 0.12 10 11 18 
E.coli 70 4 0.12 0.015 0.03 0.12 0.25 0.12 0.25 0.25 <0.008 0.015 16 8 18 
E.coli 97 8 64 0.5 0.12 0.25 0.12 0.25 128 0.03 0.06 0.12 17 16 15 
E.coli 252 128 64 4 0.25 0.25 0.03 0.015 >128 0.06 0.015 0.03 11 0 16 
E.coli 155 64 128 0.12 0.015 0.25 0.25 0.12 >128 0.25 0.03 0.12 14 13 18 
E.coli 128 4 128 0.03 0.25 0.12 0.12 0.12 >128 0.015 <0.008 0.06 9 19 0 
E.asb 192 8 64 0.060 0.12 0.12 0.25 0.015 128 0.25 0.06 0.015 10 21 19 
Ste.mal 8 >128 128 16 32 128 8 128 >128 4 128 8 0 13 10 
K.pne 122 128 64 0.25 0.5 0.25 0.12 0.12 >128 0.25 0.03 0.06 16 11 17 
E.coli 219 >128 0.25 0.5 0.25 0.25 0.03 0.015 1 0.03 0.06 0.03 16 13 15 
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                                                   Break point (Mg/L) zone diameter (mm) 
 4 16 4 2 2 4 2 8 4 4 1 12 13 16 
          Isolates SXT PIP CAZ CTX ATM GEN FEP AMP MER IMP ERT STREP SPEC KAN 
E.clo 4 32 16 0.12 0.015 0.25 0.015 0.25 8 0.12 0.015 0.12 10 13 15 
E.coli 92 64 64 0.03 0.12 0.12 0.06 0.015 >128 0.015 0.06 0.015 17 15 18 
E.coli 13 128 64 0.060 0.03 0.25 0.12 0.12 128 0.25 0.12 0.12 0 10 0 
E.coli 266 4 32 0.12 0.25 0.12 0.03 0.015 128 0.03 0.06 0.015 0 16 10 
E.coli 267 4 64 0.03 0.12 0.03 0.015 0.25 128 0.12 0.015 0.12 9 13 18 
E.coli 10 64 16 0.25 0.5 0.06 0.06 0.015 2 0.015 0.12 0.03 8 16 20 
E.coli 36 4 64 0.5 0.015 0.015 8 0.12 128 0.06 0.03 0.12 10 15 15 
E.coli 121 4 64 0.060 0.25 0.25 0.12 0.015 >128 0.25 0.12 0.06 18 17 15 
E.coli 98 4 64 0.12 0.12 0.12 0.5 0.015 >128 <0.008 <0.008 0.015 9 15 15 
E.coli 209 128 64 0.03 0.03 0.25 0.25 0.25 >128 0.25 0.06 0.12 0 9 15 
E.coli 268 4 128 0.25 0.25 0.12 0.03 0.015 >128 0.03 0.015 0.03 9 13 20 
E.coli 170 128 32 0.015 0.015 0.25 0.12 0.12 64 0.25 0.12 0.12 8 17 20 
E.coli 5 32 16 4 4 0.12 0.015 0.015 4 <0.008 <0.008 0.06 9 13 15 
E.coli 105 64 64 0.060 0.5 0.015 0.06 0.03 128 0.06 0.06 0.015 9 12 0 
E.coli 117 4 64 0.03 0.12 8 0.12 0.25 >128 0.25 0.12 0.12 15 18 19 
E.clo 193 128 128 32 32 >128 0.25 8 >128 0.015 0.015 0.03 7 0 18 
E.clo 206 128 128 8 64 >128 0.03 4 >128 0.25 0.06 0.12 8 0 18 
E.clo 176 0.060 8 0.25 0.5 0.12 0.25 0.015 16 0.03 0.03 0.12 17 21 17 
E.clo 207 0.12 4 0.12 0.12 0.06 0.12 0.03 8 0.12 0.015 0.015 16 18 20 
K.pne 72 0.5 16 0.5 0.25 0.12 0.03 0.12 32 0.015 0.12 0.06 19 19 17 
K.pne 94 0.12 16 0.060 0.015 0.03 0.015 0.015 64 0.015 <0.008 0.12 20 21 19 
K.pne 200 0.25 16 0.03 0.5 0.25 0.06 0.06 16 0.03 0.12 0.03 18 18 18 
K.pne 201 0.12 16 0.015 0.03 0.06 0.03 0.015 32 0.015 0.06 0.12 19 19 20 
K.pne 111 0.5 4 0.5 0.25 0.015 0.12 0.12 8 0.03 0.015 0.015 16 18 17 
K.pne 261 0.060 32 0.12 0.06 0.06 0.015 0.25 64 0.015 0.12 0.06 17 20 20 
K.pne 259 0.12 8 0.25 0.12 0.25 0.06 0.06 16 0.015 0.03 0.015 15 18 17 
K.oxy 248 0.25 16 0.5 0.5 0.03 0.5 0.015 32 0.25 0.12 0.03 19 19 19 






                                                   Break point (Mg/L) zone diameter (mm) 
 4 16 4 2 2 4 2 8 4 4 1 12 13 16 
          Isolates SXT PIP CAZ CTX ATM GEN FEP AMP MER IMP ERT STREP SPEC KAN 
K.oxy 154 0.5 16 0.5 0.015 0.06 0.03 0.03 8 0.25 0.12 0.12 16 17 20 
K.oxy 28 0.060 4 0.12 0.25 0.015 0.12 0.06 8 <0.008 0.5 0.015 17 19 17 
E.coli 218 0.25 16 0.060 0.03 0.12 0.25 0.015 16 0.06 0.12 0.015 19 18 18 
E.coli 220 0.12 32 0.03 0.06 0.06 0.015 0.12 64 0.12 0.06 0.03 18 20 17 
E.coli 221 0.5 4 0.015 0.5 0.015 0.06 0.25 8 0.015 0.015 0.12 17 17 17 
E.coli 226 0.25 16 0.060 0.12 0.03 0.03 0.12 32 0.25 0.06 0.03 16 19 20 
E.coli 234 0.5 8 0.5 0.03 0.12 0.25 0.25 16 0.12 0.12 0.06 15 18 17 
E.coli 91 1 1 0.12 0.25 0.25 0.12 0.06 2 <0.008 <0.008 0.015 18 21 19 
E.coli 190 0.12 0.06 0.25 0.015 0.12 0.015 0.25 0.5 0.25 0.12 0.06 20 17 17 
E.coli 177 0.060 0.25 0.060 0.12 0.03 0.06 0.015 0.5 0.03 0.015 0.03 19 19 18 
E.coli 140 0.25 0.25 0.03 0.06 0.06 0.03 0.12 0.5 0.06 0.06 0.12 17 17 17 
E.coli 9 1 0.12 0.5 0.03 0.015 0.25 0.25 0.5 0.25 0.03 0.06 16 18 20 
E.coli 245 0.5 16 0.015 0.25 0.06 0.12 0.03 16 0.015 0.12 0.015 15 20 17 
E.coli 101 2 32 0.25 0.06 0.12 0.25 0.06 64 0.25 0.12 0.06 18 17 20 
E.coli 171 0.060 0.12 0.12 0.015 0.25 0.03 0.015 0.5 0.03 0.03 0.03 20 19 18 
E.coli 208 0.25 8 0.5 4 0.06 0.25 0.12 16 0.25 0.12 0.12 16 18 17 
E.coli 37 2 0.12 0.060 0.06 0.015 0.12 0.03 1 <0.008 <0.008 0.06 17 21 19 
E.coli 63 0.5 16 0.03 0.5 0.06 0.25 0.25 16 0.12 0.12 0.015 20 17 17 
E.coli 65 0.060 16 0.015 0.12 0.12 0.25 0.06 32 0.06 0.06 0.06 19 19 20 
E.coli 15 0.12 0.5 0.03 0.25 0.03 0.03 0.25 1 0.25 0.015 0.03 17 18 19 
E.coli 59 0.25 0.5 0.5 0.03 0.25 0.5 0.12 1 0.015 0.12 0.015 16 20 17 
E.coli 60 2 16 0.060 0.5 0.06 0.25 0.03 32 0.25 0.03 0.03 15 17 18 
E.coli 73 0.5 1 0.5 0.015 0.015 0.015 0.06 0.5 0.03 0.12 0.015 18 18 17 
E.coli 52 2 16 0.12 0.06 0.06 0.06 0.25 32 0.12 <0.008 0.06 19 21 19 
E.coli 17 0.060 0.25 0.25 0.25 0.12 0.03 0.015 0.5 0.25 0.06 0.12 16 17 17 
E.coli 19 0.25 16 0.060 0.12 0.25 0.25 0.06 16 <0.008 0.12 0.06 17 20 17 
E.coli 29 0.12 1 0.015 0.06 0.06 0.12 0.03 0.25 0.25 0.015 0.03 15 19 20 





                                                   Break point (Mg/L) zone diameter (mm) 
 4 16 4 2 2 4 2 8 4 4 1 12 13 16 
          Isolates 
SXT PIP CAZ CTX ATM GEN FEP AMP 
MER IMP ERT 
STREP SPEC KAN 
E.coli 258 0.060 16 0.5 0.03 0.12 0.5 0.03 16 0.12 0.03 0.06 15 21 17 
E.coli 260 0.25 16 0.25 0.06 0.06 0.03 0.12 32 0.015 0.12 0.12 16 17 18 
E.coli 276 2 1 0.5 0.25 0.03 0.25 0.015 0.5 0.25 0.06 0.03 20 18 17 
E.coli 166 0.5 2 0.12 0.06 0.12 0.015 0.06 1 0.03 <0.008 0.06 19 21 18 
E.coli 182 0.060 16 0.5 0.12 0.06 0.06 0.015 16 <0.008 0.12 0.015 17 17 17 
E.coli 47 0.25 1 0.060 0.03 0.015 0.03 0.12 0.25 <0.008 0.03 0.12 16 21 19 
E.coli 281 0.12 32 0.03 0.015 0.06 0.5 0.03 64 0.25 0.06 0.06 15 17 17 
Ser.mar 263 0.5 32 0.015 0.06 0.25 0.12 0.06 32 0.06 <0.008 0.12 18 20 18 
Ser.mar 272 0.5 16 0.5 0.03 0.06 0.03 0.03 8 0.03 0.03 0.06 20 19 17 
Ser.mar 264 1 32 0.25 0.5 0.12 0.015 0.12 64 <0.008 0.015 0.12 16 20 19 
M.morg 279 0.5 2 0.12 0.25 0.03 0.06 0.06 4 0.06 <0.008 0.015 17 18 17 
M.morg 247 1 16 0.25 0.12 0.06 0.03 0.12 32 0.015 0.06 0.03 19 20 20 
Ste.mal 253 32 32 8 16 16 2 8 64 64 32 8 2 10 8 
Ste.mal 1 32 16 16 32 8 8 16 32 4 128 16 4 7 9 
Ste.mal 2 >128 32 8 16 4 16 32 32 4 64 4 5 9 10 
Ste.mal 16 64 64 16 64 4 16 32 64 8 64 32 6 5 12 
                
E.clo E1720 >128 >128 64 >128 >128 8 8 >128 64 >128 64 - - - 
E.clo E4293 >128 >128 64 >128 >128 8 8 >128 64 >128 32 - - - 
E.clo E4303 >128 >128 32 >128 >128 8 8 >128 8 2 8 - - - 
 
Abbreviations: CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; PIP = piperacillin; SXT = co-trimoxazole; GEN = gentamicin;      
                         ERT = ertapenem; IMI = imipenem; MER = meropenem; ATM=aztreonam; AMP=ampicillin; STREP = streptomycin;  





A plasmid gel picture showing detectable plasmids. 
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